Meltrins

Description

TECHNICAL FIELD

[0002] This invention relates to Meltrins and polypeptides of the respective domains thereof; DNAs encoding the same; antisense oligonucleotides for these DNAs; various antibodies against these Meltrins and the polypeptides of the respective domains thereof; expression vectors comprising the DNAs; transformants constructed by using these expression vectors; a process for producing the above-mentioned meltirins and the polypeptides of the respective domains thereof by means of the transformants; and medical compositions comprising the Meltrins or Meltrin antagonists as an effective ingredient.

BACKGROUND ART

[0003] In the course of myotube formation, myoblasts, which have divided from myogenic cells originating in undifferentiated mesodermal cells and grown to differentiate, will start synthesizing muscle-specific substances such as myosin and actin after its final division, and will lose cell boundaries at the fusion surface to be tansformed into multinucleate syncytium named myotube through adhesion and fusion of cytoplasmic membranes with neighbouring cells of the same kind.

[0004] There have been already reported several kinds of membrane proteins involved in the myotube formation, such as N-Cadherin (Knudsen, K. A. et al., Expl. Cell Res., 188, 175-184 (1990), Merge, R. M. et al., J. Cell Sci., 103, 897-906 (1992)), M-Cadherin (Donalies, M. et al., Proc. Natl. Acad. Sci., U.S.A. 88, 8024-8028 (1991)), N-CAMs (Merge, R. M. et al., J. Cell Sci., 103, 897-906 (1992) and others), V-CAMs and Integrins (Rosen, G. D. et al., Cell 69, 1107-1119 (1992) and others).

[0005] However, the molecular mechanism has not yet been sufficiently understood concerning the course of formation of the multinucleate syncytium named myotube through adhesion and fusion of the cytoplasmic membranes of the myoblasts with each other.

[0006] On the other hand, the substances named “fusion peptides” have been known as an adhesion factor involved in the course of infection of cells with viruses (Morrison, T. G. Virus Res., 10, 113-136 (1988) and the others). Fertilin, which was recently isolated as a factor involved in sperm-egg adhesion, has been found to contain a sequence similar to the fusion peptide of rubella virus (Biobel, C. P. et al., Nature 356, 248-252 (1992) and the others).

[0007] Many substances having adhesion activity are known as mentioned above, and substances which may inhibit the activity of Integrins and the like have been developed and studied as potential medical agents.

[0008] The present inventors have now isolated novel substances involved in adhesion. Particularly, on the assumption that some fusion peptide-like adhesion factor like in sperm-egg adhesion may be involved in adhesion and fusion of the myoblasts with each other in the course of myotube formation, the novel substances involved in cell adhesion have been cloned and named “Meltrins” , by using highly conserved sequences in Fertilin α and β as a probe.

DISCLOSURE OF INVENTION

[0009] The present invention relates to novel substances “Meltrins.” “Meltrins” are characterized as proteins which are expressed in the course of differentiation-induction of muscle cells and to contain the highly conserved sequences in Fertilin α and β. Meltrins are also characterized as proteins which are involved in fusion, adhesion, or aggregation of cells. Thus, some kinds of cells such as muscle ones may fuse, aggregate or adhere via Meltrins.

[0010] Cell fusion means that more than two cells fuse with each other to form one multinucleate syncytium. Adhesion of cells means that more than two cells adhere to each other. Aggregation of cells means that more than two cells (particularly the cells present in liquid) flock together to form a mass of cells. It may be considered that cells adhere to each other, followed by cell fusion and aggregation.

[0011] The origin of the present Meltrins is not specifically limited. Accordingly, Meltrins in the present specification comprise polypeptides originating in any animals as long as they have the above features, unless otherwise particularly noted. As will be demonstrated in the following examples, at least three kinds of molecules (α, β and γ) have been isolated from one animal species. Meltrins in the present specification therefore comprise any one of the above three molecules.

[0012] The specific examples of Meltrins of the present invention are mouse Meltrins α, β and γ, which are characterized by amino acid sequences shown in FIG. 2a˜FIG. 2j,

FIG. 3

a˜FIG. 3j and FIG. 4a˜

FIG. 4

i, respectively, or partial sequences thereof.

[0013] Other examples may contain human Meltrins α, β and γ, which are characterized by amino acid sequences shown in any one of FIG. 12a˜FIG. 12b, FIG. 15a˜FIG. 15f or FIG. 23a˜FIG. 23b; any one of FIG. 16 or FIG. 17a˜FIG. 17c; or FIG. 13a˜FIG. 13d, respectively, or partial sequences thereof.

[0014] The above amino acid sequences should be considered only examples of Meltrins of the present invention. Any variant of the above amino acid sequences wherein a part of the sequences has changed due to deletion, substitution, addition, insertion and the like of amino acids is therefore contained in Meltrins of the present invention, as long as it is expressed in muscle cells, and have the highly conserved sequences in Fertilin α and β or is involved in fusion, adhesion or aggregation of cells. As cleared now by the present inventors, a high homology is seen in the part from disintegrin domain to cysteine-rich region of mouse amino acid sequences shown in FIG. 2a˜FIG. 2j and human amino acid sequences shown in FIG. 12a˜FIG. 12b. It is considered that such substances as showing homology of about 80% or more, preferably about 90% or more to the above amino acid sequences may keep the function as Meltrin. Particularly, it is believed that the substances having the sequences with homology of about 80% or more, preferably about 90% or more to the region from metalloproteinase domain to disintegrin domain of mouse or human Meltrins α, β and γ will have substantially the same activity, even if all of the other sequences are different from them. Accordingly, Meltrins of the present invention may include substances having a high homology to the above amino acid sequences or to a part thereof and showing substantially the same activity as mouse or human Meltrins.

[0015] In other words, Meltrins of the present invention may be characterized by having amino acid sequences encoded by base sequences that may hybridize the sequences complementary to the base sequences encoding any one of the amino acids shown in FIG. 2a˜FIG. 2j, FIG. 3a˜FIG. 3j, FIG. 4a˜FIG. 4i, FIG. 12a˜FIG. 12b, FIG. 13a˜FIG. 13d, FIG. 15a˜FIG. 15f, FIG. 16, FIG. 17a˜FIG. 17cor FIG. 23a˜FIG. 23b.

[0016] Meltrins exist in bodies as a membrane protein consisting of intracellular domain, transmembrane domain, and extracellular domain; and as a soluble protein having no transmembrane domain. The extracellular domain contains precursor domain, metalloproteinase domain, disintegrin domain, and cysteine-rich region. Meltrin a has a fusion peptide-like sequence in its cysteine-rich region (Refer to FIG. 8).

[0017] The disintegrin domain is indispensable for the function of Meltrins such as adhesion, fusion and aggregation of cells. On the other hand, the precursor and metalloproteinase domains are thought to be regulating sequences for Meltrins to show the activity in a specific organ or tissue, or under specific conditions. It is known that the disintegrin found in snake venom will adhere to platelet IIb/IIIa. It is therefore presumed that the disintegrin domain by itself may have the function to adhere to cells. The metalloproteinase domain may act by itself as a protease as such.

[0018] The present invention relates to polypeptides comprising any part of Meltrins. The present polypeptides include the respective domain per se of Meltrins, polypeptides comprising at least the respective domain of Meltrins, any part of the sequences of Meltrins, polypeptides comprising at least any part of the sequences of Meltrins, and polypeptides comprising at least the sequence having the combination of any of the respective domains of Meltrins and any part of Meltrins in any order. The present invention may further include the above polypeptides which are chemically modified or formed into salts thereof.

[0019] The preferable examples of the present polypeptides include polypeptides consisting of a part of the disintegrin domain, polypeptides consisting of the disintegrin domain per se, polypeptides comprising at least the disintegrin domain, polypeptides comprising at least the disintegrin and cysteine-rich regions, polypeptides comprising at least the metalloproteinase, disintegrin and cysteine-rich regions, polypeptides consisting of a part of the metalloproteinase domain, and polypeptides consisting of the metalloproteinase domain per se.

[0020] There may be mentioned as other preferable examples of the present polypeptides those comprising at least the disintegrin and cysteine-rich regions, but not comprising the transmembrane domain, or comprising neither the transmembrane domain nor intracellular domain; and those comprising at least the metalloproteinase, disintegrin and cysteine-rich regions, but not comprising the transmembrane domain, or comprising neither the transmembrane domain nor intracellular domain. Such polypeptides comprising no transmembrane domain are a soluble one which will be secreted through a cell membrane into an extracellular area. The soluble polypeptides may be collected froma supernatant of the culture medium of cells. When optionally combined downstream of a suitable signal sequence and expressed by cells in a genetic engineering process, it will be secreted into the culture supernatant and advantageously collected therefrom with a high efficiency.

[0021] The amino acid sequences in FIG. 2a˜FIG. 2j, FIG. 3a˜FIG. 3j, FIG. 4a˜FIG. 4i, FIG. 12a˜FIG. 12b, FIG. 13a˜FIG. 13d, FIG. 15a˜FIG. 15f, FIG. 16, FIG. 17a˜FIG. 17cand FIG. 23a˜FIG. 23b, which correspond to the precursor domain, metalloproteinase domain, disintegrin domain, cysteine-rich region, intracellular domain, and transmembrane domain of mouse and human Meltrins α, β and γ, are discussed in the Examples. It should be noted, however, that the polypeptides having the above corresponding amino acid sequences constitute only examples of the polypepetides of the present invention. The polypeptides essentially comprising the same amino acid sequences also belong to the scope of the present invention. Thus, the boundaries of each domain are not limited to those defined in the Examples. And the polypeptides comprising the domains wherein the boundaries are shifted to N-, C-terminals or both by 1 to about 20 amino acids from the boundaries defined in the Examples are contained in the polypeptides of the present invention, as long as they have substantially the same function as that of the above polypeptides. Similarly, the polypeptides wherein a part of the amino acid sequences has changed due to deletion, substitution, addition, insertion and the like of amino acids are therefore contained in the polypeptides of the present invention, as long as they have substantially the same function as that of each domain.

[0022] As it is considered that the polypeptides comprising such amino acid sequences as showing homology of about 80% or more, preferably about 90% or more to the amino acid sequences in each domain of the above figures may have the same function as that of the polypeptides of the present invention, they are also considered to be contained in the present invention.

[0023] Meltrins of the present invention may be used to bond cells to each other or to apparatuses such as a plate. They may be also fused with any other substances to efficiently deliver the substances to muscle cells upon its application into culture systems of the muscle cells, tissues or bodies.

[0024] On the other hand, the polypeptides comprising at least a part of Meltrins may be added to the culture systems to competitively inhibit the adhesion, fusion or aggregation of cells. Particularly, the disintegrin domain per se, a part thereof, or a soluble polypeptide comprising the disintegrin domain may be used as an effective ingredient in a medical composition for inhibiting the adhesion of cells. For example, such medical composition may be used as an anticoagulant to inhibit thrombus formation or blood coagulation, and be used to treat thrombosis, DIC and multi-organ failure. Furthermore, since it is considered that adhesion factors such as integrin family are involved in metastasis of cancer cells, the polypeptides comprising the disintegrin domain may be used as a drug for inhibiting the growth of cancers, or the adhesion of cancer cells to other cells so as to prevent their metastasis. In addition to the above, it is known that-the adhesion of cells plays an important role in the formation of osteoclasts. The examples will demonstrate that Meltrins are involved in the adhesion in the formation of osteoclasts, and anti-Meltrin antibodies may inhibit the formation of osteoclasts and the increase of bone resorption Accordingly, the polypeptides of the present invention comprising disintegrin domain of Meltrins, particularly of Meltrins α or β, may be used as an effective ingredient in a medical composition for inhibiting the increase of bone resorption, like as anti-Meltrin antibodies.

[0025] Among the polypeptides comprising at least a part of Meltrins of the present invention, those comprising the metalloproteinase domain may act as a protease by itself, or be used to competitively inhibit the activity of other proteases so that they may be utilized as a drug for treating inflammatory diseases.

[0026] The polypeptides and Meltrins of the present invention may also be used as antigens for producing antibodies.

[0027] The present invention also relates to DNAs comprising the base sequences encoding the amino acid sequences of Meltrins of the present invention or the polypeptides comprising any parts thereof.

[0028] The above DNAs include any type of DNAs such as genomic DNAs and cDNAs.

[0029] The origin of the present DNAs is not specifically limited. The examples of the present DNAs are those encoding mouse Meltirns α, β, and γ, or the polypeptides comprising any parts thereof, which are characterized by the coding regions shown as the base sequences in FIG. 5a˜FIG. 5j, FIG. 6a˜FIG. 6h, and FIG. 7a˜FIG. 7e, respectively, or partial sequences thereof. Other examples are those encoding human Meltrins α, β, and γ, or the polypeptides comprising any parts thereof, which are characterized by the coding regions of the sequences shown as the base sequences in any one of FIG. 12a˜FIG. 12b, FIG. 15a˜FIG. 15for FIG. 23a˜FIG. 23b; any one of FIG. 16 or FIG. 17a˜FIG. 17c; or FIG. 13a˜FIG. 13d, respectively, or partial sequences thereof.

[0030] The base sequences in the above figures, which correspond to the precursor domain, metalloproteinase domain, disintegrin domain, cystein-rich domain, intracellular domain, and transmembrane domain of mouse and human Meltrins α, β and γ, are discussed in the Examples. It should be noted, however, that they constitute only examples of the DNAs of the present invention. The DNAs essentially comprising the same base sequences also belong to the scope of the present invention. Thus, the boundaries of each domain are not limited to those defined in the Examples. And the DNAs comprising sequences encoding the domains wherein the boundaries are shifted to 5′-, and/or 3′-ends by 1 to about 60 base pairs from the boundaries defined in the Examples are contained in the DNAs of the present invention, as long as they encode the polypeptides having substantially the same function as that of each domain.

[0031] In addition of the above base sequences, the present DNAs include those comprising the base sequences or partial sequences thereof, which encode the same amino acid sequences as above prepared by means of chemical synthesis or genetic engineering in consideration of degeneracy of codons.

[0032] As cleared now by the present inventors, a high homology is seen in mouse and human Meltrins. It is therefore considered that the substances showing homology of about 80% or more, preferably about 90% or more to the above amino acid sequences may keep the function as Meltrin, and that DNAs encoding such homologous polypeptides will hybridize with each other. Accordingly, the present DNAs also include DNA fragments which may be obtained by hybridization under stringent conditions using the DNAs having the base sequences complementary to those in the above figures as a probe.

[0033] The DNAs of mouse or human Meltrins α,β and γ, or partial sequences thereof may be inserted into plasmid vectors. Strains of E. coli transformed by the same plasmid vectors have been deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology.

[0034] The present DNAs may be prepared by known methods. The cDNAs, for example, may be prepared by using cDNA library and known PCR (e.g., Michael A. I. et al., PCR Protocols, a guide to method and application, Academic Press, 1990) with degenerative primers for a part of the amino acid sequences (for example, the degenerative primer encoding the amino acid sequences of the disintegrin domain) shown in FIG. 2a˜FIG. 2j, FIG. 3a˜FIG. 3j, FIG. 4a˜FIG. 4i, FIG. 12a˜FIG. 12b, FIG. 13a˜FIG. 13d, FIG. 15a˜FIG. 15f, FIG. 16, FIG. 17a˜FIG. 17c and FIG. 23a˜FIG. 23b. The present DNAs may also be prepared by hybridization method using a probe prapared on the basis of the base sequences of the above amplified DNA fragments.

[0035] As demonstrated in the Examples, the preferable source of cDNA library include cells obtained by inducing myoblast to differentiate, bone marrow and fetal pulmonary cells. Known cDNA libraries prepared from placenta, chorionic cells and fetal cells may also serve as the source of cDNA library in the present invention.

[0036] Among the present DNA, one encoding the polypeptide in which any parts of Meltrins are combined in any order may be prepared by the following steps. That is, each DNA fragment encoding any part of Meltrins is amplified by PCR, in which the primers may be optionally modified in order to provide an appropriate restriction enzyme site. The amplified DNA fragments are ligated with each other by DNA ligase, so that a reading frame should not be shifted.

[0037] The present DNAs may be used for producing the Meltrins or polypeptides of the present invention by means of genetic engineering. Such prodution may be carried out with reference to known methods (for example, Sambrook J. et al., Molecular Cloning a Laboratory Manual 2nd ed., Cold Spring Harbor Laboratory, New York, 1989).

[0038] The present DNAs inserted into suitable vectors may also be used in gene therapy. The base sequence encoding any physiologically active substances is fused downstream of the present DNAs followed by insertion of the resulting fused DNA into a vector originated in an appropriate virus, and cells in a living body are transformed with the resulting vector, so that the physiologically active substances may be expressed as a fused protein with Meltrins of the present invention. The thus expressed physiologically active substances will be delievered near to the cells to which Meltrins adhere.

[0039] The present invention further relates to antisense oligonucleotides and derivatives thereof for the DNAs encoding Meltrins of the present invention or for the polypeptides comprising any part thereof.

[0040] The present antisense oligonucleotides and derivatives thereof are characterized by their base sequences complementary to those encoding Meltrins or a part thereof, or by their function to inhibit the expression of Meltrins or the polypeptides comprising any part thereof. The antisense oligonucleotides and derivatives thereof characterized by the latter feature include those complementarily bonding to the non-coding regions existing upstream or downstream of the coding regions of Meltrins as well as those complementarily bonding to the coding regions of Meltrins or any part thereof.

[0041] The examples of the present antisense oligonucleotides and derivatives thereof include the base sequences complementary to the DNAs of the present invention or any part thereof, particularly to those shown in FIG. 5a˜FIG. 5j, FIG. 6a˜FIG. 6h, FIG. 7a˜FIG. 7e, FIG. 12a˜FIG. 12b, FIG. 13a˜FIG. 13d, FIG. 15a˜FIG. 15f, FIG. 16, FIG. 17a˜FIG. 17cand FIG. 23a˜FIG. 23b. Uracil (U) may be used instead of thymine (T) as a complementary base to adenine (A).

[0042] The derivatives of the present antisense oligonucleotides include any one that is similar to the antisense oligonucleotides in steric structure and function, such as those wherein other substances are bound to 3′- or 5′-end of the oligonucleotides; those wherein at least one of bases, sugars or phosphoric acids in the oligonucleotides has substitution or modification; those having non-naturally occurring bases, sugars or phosphoric acids; and those having back bone other than that of sugars-phosphoric acids.

[0043] The present antisense oligonucleotides and derivatives thereof may be prepared by known methods (for example, ed., Stanley T. Crooke and Bernald Lebleu, in Antisense Research and Applications, CRC Publishing, Florida, 1993).

[0044] The present antisense oligonucleotides of a naturally occurring type may be prepared by chemically synthesizing sense-primers and antisense-primsers having the base sequences complementary to 3′- or 5′-end of the antisense oligonucleotide sequences, followed by PCR using the Meltrin genes or RNAs encoding Meltrins as a template. Otherwise, the derivatives of the antisense oligonucleotides such as a methylphosphonate and phosphorothionate types may be prepared by means of a chemical synthesizer (e.g., Perkin Elmer Japan Co., Type 394) accoding to the manual attached to the chemical synthesizer, followed by, if necessary, purification of the synthesized products in HPLC method using reversed phase chromatography and the like.

[0045] The present antisense oligonucleotides and derivatives thereof may be labelled with radioisotopes, fluorescent substances, enzymes or luminescent substances and used as a probe for detecting the existence of Meltrins or any part thereof in a sample. The present antisense oligonucleotides may also be used as a medical composition for inhibiting the expression of Meltrins in a living body.

[0046] For the purpose of inhibiting the expression of Meltrins by using the present antisense oligonucleotides and derivatives, they may be solubilized or suspended in a suitable solvent, enclosed in a liposome, or inserted into a suitable vector.

[0047] It is preferred that the present antisense oligonucleotides and derivatives thereof used in the medical composition should have a pharmaceutically acceptable purity and be used in a pharmaceutically acceptable way.

[0048] As already mentioned in the above, it is considered that Meltrins are involved in formation of osteoclasts, growth and metastasis of cancers as well as skeletal myogenesis. Accordingly, the present antisense oligonucleotides and their derivatives which are capable of inhibiting the expression of Meltrins may be used in treatment and prevention of cancers, treatment of osteoporosis and hypercalcemia by inhibiting bone resorption.

[0049] The present invention also relates to antibodies recognizing Meltrins of the present invention or the polypeptides comprising at least any part thereof. In other words, they include those recognizing only Meltrins of the present invention, those recognizing only the polypeptides of the present invention and those recognizing both of them.

[0050] The present antibodies include those cross reacting with other polypeptides in addition to those specifically recognizing Meltrins and the polypeptides of the present invention. They also include those specifically recognizing any one of Meltrins α, β and γ, and those specifically recognizing more than two of Meltrins α, β and γ, as well as those recognizing only Meltrins originated in a particular animal such as human and mouse or only the polypeptides comprising at least any part thereof, and those recognizing Meltrins originated in more than two kinds of animals or the polypeptides comprising at least any part thereof.

[0051] The preferable present antidodies are those recognizing the amino acid sequences in FIG. 2a˜FIG. 2j, FIG. 3a˜FIG. 3j, FIG. 4a˜FIG. 4i, FIG. 12a˜FIG. 12b, FIG. 13a˜FIG. 13d, FIG. 15a˜FIG. 15f, FIG. 16, FIG. 17a˜FIG. 17c or FIG. 23a˜FIG. 23b, or any part thereof.

[0052] More preferably, the present antidodies are those obtained by immunization of animals with the polypeptides comprising said amino acid sequences or any part thereof as an antigen, which may be optionally conjugated with a suitable carrier.

[0053] Such preferred antibodies may be prepared by inserting DNA comprising the base sequences shown in FIG. 5a˜FIG. 5j, FIG. 6a˜FIG. 6h, FIG. 7a˜FIG. 7e, FIG. 12a˜FIG. 12b, FIG. 13a˜FIG. 13d, FIG. 15a˜FIG. 15f, FIG. 16, FIG. 17a˜FIG. 17c or FIG. 23a˜FIG. 23b or any part thereof into a suitable expression vector, tranforming a suitable host cell by the vector to produce Meltrins, which are purified from cell bodies of the transformant or culture medium and administered as an antigen. The cell bodies per se of the transformant or any cells expressing Meltrins per se may be administered as an antigen. Such transformant or cells may express any one of Meltrins α, β and γ, or more than two kinds of them. The present antibodies may be also prepared by chemically synthesizing the polypeptides having a part of the amino acid sequences of Meltrins, conjugating them with a carrier such as KLH (Keyhole Limpet Hemocyanin) and administering them as an antigen.

[0054] It is possible to prepare the present antibody that may recognize the whole of Meltrins even when the part of Meltrins is used as an antigen to be administered. It is also possible to prepare the present antibody that may recognize human Meltrins or any part thereof even when mouse Meltrins or any part thereof are used as an antigen to administered.

[0055] The antibodies of the present invention include monoclonal and polyclonal ones, and may belong to any class or subclass.

[0056] The antibodies of the present invention may be prepared according to known methods (e.g., “Meneki jikkenho (Laboratory manual of Immunology)” published by Japan Immunological Society). An example of the known methods will be described below.

[0057] A suitable cell is transformed by an expression vector comprising the coding regions of the base sequences shown in FIG. 5a˜FIG. 5j, FIG. 6a˜FIG. 6h, FIG. 7a˜FIG. 7e, FIG. 12a˜FIG. 12b, FIG. 13a˜FIG. 13d, FIG. 15a˜FIG. 15f, FIG. 16, FIG. 17a˜FIG. 17c or FIG. 23a˜FIG. 23b or any part thereof, and used as an antigen as such. Alternatively, Meltrins produced by the transformant are purified from cell bodies of the transformant or culture medium to be used as an antigen, or polypeptides consisting of amino acid sequences shown in the above figures are chemically synthesized, cojugated with a carrier such as KLH (Keyhole Limpet Hemocyanin) and purified to be used as an antigen.

[0058] Animals are inoculated with the antigen thus prepared, alone or together with a suitable adjuvant such as Freund's complete adjuvant (FCA) or Freund's incomplete adjuvant (FIA), subjected to boosting at two to four-week intervals. After boosting, the blood is drawn from the animals and antiserum is obtained therefrom. Animals to be immunized may be selected from rat, mouse, rabbit, sheep, horse, fowl, goat, pig, cattle and the like, depending on the kind of the antibody to be desired. Polyclonal antibodies may be obtained by purification of the antiserum by known methods such as salting-out, ion-exchange chromatography, affinity chromatography and any combination thereof.

[0059] Monoclonal antibodies may be prepared as follows. Antibody-producing cells such as spleen cells and lymphocytes are collected from the immunized animals, fused with myeloma and the like by known methods using polyethyleneglycol, Sendai virus, electrical pulse to give hybridomas. Clones which produce the antibodies bonding to Meltrins of the present invention are then selected and cultured. Monoclonal antibodies of the present invention are purified from the culture supernatant of the selected clones by known methods such as salting-out, ion-exchange chromatography, affinity chromatography and any combination thereof.

[0060] The present antibodies may be neutralizing antibodies, which inhibit the fusion, adhesion or aggregation of cells by Meltrins. The neutralizing antibodies of the present invention include those that can completely inhibit the activity of Meltrins, and those partially inhibit the same.

[0061] The neutralizing antibodies may be screened by adding antiserum or culture supernatant of the hybridomas to the culture system of Meltrin-expressing cells to evaluate the degree of inhibition of fusion or aggregation of cells. After the screening, the desired antibodies may be purified from the thus selected antiserum or culture supernatant of the hybridomas by the known methods.

[0062] The antibodies of the present invention include Fab, F(ab′), F(ab′)2 and Fv, as long as they recognize and bond to the present polypeptides or any part thereof. A single chain Fv may be also included in the present antibodies, which is obtained by constructing a gene encoding the single chain Fv wherein H and L chains are linked into a single chain and being expressed by a suitable host cell. Chimera antibodies, human antibodies and humanized antibodies are also included in the present invention, as long as they recognize and bond to the present polypeptides or any part thereof.

[0063] For example, the chimera anitbodies may be prepared by substituting a gene encoding the constant region of human antibodies for a gene encoding the constant region of the mouse antibodies recognizing Meltrins or the polypeptides of the present invention, expressing the thus reconstituted gene in animal cells. The human antibodies may be prepared by, for example, in vitro sensitization method (Borrebaeck, C. A. K. J. Immunol., Meth., 123, 157, 1989) or the method using SCID mouse (Toshio KUDO, Tissue Culture, 19, 61-65, 1993). The humanized antibodies may be prepared by reconstituting a gene so that complementary determining regions (CDR) of the human antibodies are replaced with those of the mouse antibodies, and expressing the gene in animal cells (Carter et al., Pro. Nat. Acad. Sci, 89, 4285, 1992).

[0064] If necessary, amino acids in a framework of the variable region of the humanized antibodies thus reconstituted may be replaced, so that the framework should have a high homology to that of the mouse antibodies and CDR of said humanized antibodies may form an appropriate antigen-binding site. The preferred examples of the humanized antibodies are those having the same CDR as the neutralizing antibodies F932-15-2 and F937-9-2. For the preparation of these preferred humanized antibodies, the DNA encoding the antibodies is prepared from the hyridoma F932-15-2 or F937-9-2, and linked with the DNAs encoding human antibodies so that the sequences other than CDRs should originate in the human antibodies. Any variation may be optionally introduced into the DNA encoding the framework portion. The thus obtained DNA is then inserted into a suitable expression vector to transform a suitable cell, and the humanized antibodies are purified from the culture supernatant of the transformant.

[0065] The present antibodies may be labelled with fluorescent substances, enzymes, luminescent substances or radioisotopes to detect Meltrins or their decomposed products present in body fluid or tissues. Since it is considered that Meltrins are involved in formation of myotubes, resorption of bone and metastasis of cancers as already mentioned in the above, the detection of the existence of Meltrins in body fluid or tissues would make it possible to estimate the progress of diseases and prognosis and to confirm the effects of treatments. The present antibodies may be also used to provide an antibody affinity column, or to detect Meltrins in a fraction during the course of purification of Meltrins.

[0066] The neutralizing antibodies of the present invention may serve as an effective ingredient of a medical composition for inhibiting bone resorption, inflammatory diseases, blood coagulation and metastasis of cancers, owing to their ability to inhibit fusion or adhesion of cells. They may serve as an agent used in culture to inhibit the aggregation of cultured cells. When used as the effective ingredient of the medical composition, the human or humanized antibodies are preferred from the viewpoint of their antigenicity.

[0067] Also, the present invention relates to a vector comprising the DNA of the present invention. The present vector may further contain, if necessary, an enhancer sequence, promoter sequence, ribosome-binding sequence, base sequence for amplification of the number of copies, sequence encoding signal peptides, sequences encoding other polypeptides, poly(A)-additional sequence, splicing sequence, origin of replication, base sequence of the gene for selective markers and so on.

[0068] The present vector may be prepared by inserting the DNAs of the present invention into any vectors according to known methods (e.g., Molecular Cloning, a Laboratory Manual 2nd ed., Cold Spring Harbor Laboratory, New York, 1989). The preferable examples of the DNAs encoding Meltrins or any part thereof have been already disclosed in the present specification. The present vectors include a plasmid vector, phage vector and virus vector; pUC118, pBR322, pSV2-dhfr, pBluescriptII, PHIL-S1, λZap II, λgt10, pAc700, YRP17, pEF-BOS and pEFN-II being preferred.

[0069] The preferred vectors of the present invention may optionally comprise the origin of replication, selective markers, and promoter in addition to the DNAs encoding Meltrins or the polypeptides comprising at least any part thereof so as to be used to express Meltrins or the same polypeptides. As the origin of replication, ColEl, R factor, F factor and so on may be used in the vectors for E.coli; SV40- or adenovirus-derived ones in the vectors for animal cells; and ARS1-derived one in the vectors for yeast. As the promoter, trp, lac and tac promoters may be used in the vectors for E.coli; SV40-, cytomegalovirus-, and adenovirus-derived ones, and those intrinsically existing in the genes of human or animals such as the promoter region of an elongation factor 1α in the vectors for animal cells; and a promoter in the vectors for yeast, especially AOX1 promoter in the case of Pichia yeast. In the addition to the above sequences, the present vectors may further comprise, if necessary, RNA splicing site, signal for poly-adenylation and the like for the transforamtion of eucaryotic cells. The present vectors may be used for the production of Meltrins or any part thereof by means of genetic engineering, and used in gene therapy for Meltrins-related diseases.

[0070] The present invention therefore relates to transformants transformed by the above vectors.

[0071] The present transformants may be prepared by transforming suitable host cells by the above vectors according to known methods (e.g., Idenshi Kogaku Handbook (Handbook of gene technology), extra edition of Jikkenigaku, Yodo, 1991)). The host cells may be selected from procaryotic ones such as E.coli and Bacillus, or eucaryotic cells such as yeast, insect cells, and animal ones. The preferred transformants of the present invention are those derived from E.coli, yeast or CHO cell as a host cell to express Meltrins or the polypeptides of the present invention.

[0072] The present invention further relates to a process for producing Meltrins or the present polypeptides comprising at least any part thereof, comprising the step of culturing the above transformants.

[0073] In the present producing process, the transformants of the present invention are cultured, optionally with amplification of the gene or expression-induction, if necessary, according to known methods (e.g., Biseibutsugaku Jikkenho (Laboratory manual of microbiology), Tokyo Kagaku Dojin, 1992). The culture mixture, i.e., the cells and culture supernatant, is collected and optionally subjected to concentration, solubilization, dialysis, and various chromatography to purify Meltrins or the present polypeptides comprising any part thereof. The purification of the present polypeptides may be carried out by an optional combination of the above known methods for the purification of proteins, and an efficient purification could be performed by using an affinity column with the antibodies of the present invention.

[0074] In the present producing process, the polypeptides of the present invention may be produced by the transformants as a fused protein with other proteins such as β-galactosidase. In such case, the fused protein should be treated with chemicals such as cyanogen bromide or enzymes such as protease in a certain step in the purification process, so that the polypeptides of the present invention may be excised.

[0075] The present invention relates to medical compositions comprising a novel effective ingredient, which is Meltrins of the present invention or Meltrin-antagonist. The “Meltrin-antagonist” means a molecule which is able to inhibit fusion, adhesion or aggregation of cells through Meltrins. It includes, for example, the present antibodies recognizing Meltrins and having a neutralizing activity, the fragments of the same antibodies, the polypeptides consisting of any part of Meltrins or any combination thereof in any order, the antisense oligonucleotides for the DNAs encoding Meltrins or derivatives thereof.

[0076] The antibodies recognizing Meltrins may be prepared by the methods already mentioned in the above, and from which the antibodies which may completely or partially neutralize fusion, adhesion or aggregation of muscle cells, osteoclasts or cancer cells are selected and used as the effective ingredient of the present medical composistions. The antibodies to be used as the effective ingredient include those prepared by administering any polypeptides as the antigen into any animals, as long as they may recognize human Meltrins and inhibit fusion, adhesion or aggregation of human muscle cells, osteoclast or cancer cells. They may be polyclonal or monoclonal ones, being preferably the human or humanized antibodies, considering the fact that the medical compositions will be administered to human. The human or humanized antibodies may be prepared according to the methods already described in the above.

[0077] The above fragments to be used as the effective ingredient in the present medical compositions include Fab, F(ab′), F(ab′)2 and Fv.

[0078] The polypeptides having any part of Meltrins or any combination thereof in any order may be used as the effective ingredient of the medical compositions, as long as they have the activity of inhibiting fusion, adhesion or aggregation of cells.

[0079] The preferable examples of the above polypeptides include those comprising a part or the whole of the disintegrin domain of Meltrins, those comprising the metalloproteinase, disintegrin and cysteine-rich regions of Meltrins, those comprising the disintegrin domain, but not comprising the transmembrane domain of Meltrins, and those comprising at least the metalloproteinase and disintegrin domains, but not comprising the transmembrane domain of Meltrins. These polypeptides may be chemically synthesized or produced by means of genetic engineering, as already mentioned in the above.

[0080] The antisense oligonucleotides or derivatives thereof to be used as the effective ingredient of the medical compositions may have any base sequences or any structure, as long as they are suitable for administration to human, and will complementarily bond to the gene for Meltrins to completely or partially inhibit their expression.

[0081] As already mentioned, Meltrins are involved in formation of osteoclasts and metastasis of cancer cells. Accordingly, the medical comosition comprising the Meltrin-antagonist as the effective ingredient may be used for the purpose of inhibition of bone resorption or metastasis of cancers. The antagonist against human Meltrin α or β is more preferably used as the effective ingredient in the medical composition for inhibition of bone resorption, while the antagonist against human Meltrin γ is more preferably used as the effective ingredient in the medical composition for inhibition of cancer metastasis.

[0082] The Meltrins or Meltrin antagonist used as the effective ingredient in the present medical composition may be formed into their salts or be modified with pharmaceutically acceptable chemical agents, as long as they will never lose their essential activities. There may be exemplilfied as the salts those with inorganic acids such as hydrochloric acid, phosphoric acid, hydrobromic acid and sulfuric acid; those with organic acids such as maleic acid, succinic acid, malic acid and tartaric acid.

[0083] The medical compositions of the present invention include those administered by any route such as oral, subcutaneous, intravenous, intramuscular, intraperitoneal, intracutaneous, and intraintestinal ones.

[0084] Any administration methods and intervals may be adopted. The present medical compositions may comprise, depending on the administration route, pharmaceutically acceptable auxiliaries such as fillers, packing agents, thickeners, binding agents, humidifying agents, disintegrating agents, surfactants, solution aids, buffers, pain-easing agents, preservatives and stabilizers. In the case of injections, for example, they may comprise stabilizers such as gelatin, human serum albumin (HSA) and polyethylene glycol; alcohols and saccharides such as D-mannitol, D-sorbitol, and glucose; and surfactants such as Polysorbate 80 (TM).

[0085] The medical compositions of the present invention may be mainly used for the prevention and treatment of osteoporosis and hypercalcemia, or the prevention of infiltration and metastasis of cancers.

[0086] The present medical compositions may be administered in an amount of about 0.1˜100 mg/kg/day, preferably of about 1˜50 mg/kg/day, more preferably of about 1˜10 mg/kg/day, depending on the conditions or ages of patients, or administration routes. It may also be continuously administered by an intravenous drip, or administered by a single dose or doses at appropriate intervals per day.

[0087] The present medical compositions may be formulated according to the conventional manners. The injection, for example, may be formulated by dissolving the Meltrins or their antagonists aseptically prepared to a pharmaceutically acceptable purity into physiological saline, buffers and the like, followed by addition of gelatin or HSA, if necessary. Such injections may also be lyophilized, which will be dissolved into distilled water for the injections, physiological saline and the like when they are used.

[0088] The screening of the substances which may bind to Meltrins, inhibit the activity of Meltrins or regulate their expression may be carried out by using the Meltrins, various polypeptides, DNAs encoding them and the like.

BRIEF DESCRIPTION OF THE DRAWINGS

[0089]

FIG. 1

a
˜FIG. 1b show the comparison between parts of mouse Meltrins α, β, γ (referred to as “Mα”, “Mβ”, “Mγ”) and the known sequences (macrophage specific antigen (MS2), Jararhagin (JR), fertilin-α (fα).

[0090]

FIG. 2

a
˜FIG. 2j show the amino acid sequence of mouse Meltrin α and its corresponding DNA sequence.

[0091]

FIG. 3

a
˜FIG. 3j show the amino acid sequence of mouse Meltrin β and its corresponding DNA sequence, wherein “N” means unidentified base.

[0092]

FIG. 4

a
˜FIG. 4i show the amino acid sequence of mouse Meltrin γ and its corresponding DNA sequence. “N” means unidentified base.

[0093]

FIG. 5

a
˜FIG. 5j show the result of DNA sequence analysis of the DNA inserted into pBSMelα, which comprises the base sequence encoding mouse Meltrin α. “N”, “M”, “W” and “S” mean unidentified bases.

[0094]

FIG. 6

a
˜FIG. 6h show the result of DNA sequence analysis of the DNA inserted into pBSMelβ, which comprises the base sequence encoding mouse Meltrin β. “N”, “M”, “W” and “S” mean unidentified bases.

[0095]

FIG. 7

a
˜FIG. 7e show the result of DNA sequence analysis of the DNA inserted into pBSMelγ, which comprises the base sequence encoding mouse Meltrin γ. “N”, “M”, “W” and “S” mean unidentified bases.

[0096]
FIG. 8 shows schematically the structures of Meltrins α, β, γ, δMP, δPro.

[0097]
FIG. 9 is a photograph of electrophoresis showing the result of Western blotting.

[0098]
FIG. 10 is a photograph of electrophoresis showing the result of Northern blotting.

[0099]

FIG. 11

a
˜FIG. 11b show fusion-promoting activity of Meltrins for myoblast.

[0100]

FIG. 12

a
˜FIG. 12b show the result of base sequence analysis of the DNA inserted into pBShuMα300, which encodes human Meltrin α. “N” and“X” mean unidentified bases and unidentified amino acids, respectively.

[0101]

FIG. 13

a
˜FIG. 13d show the result of base sequence analysis of the DNA inserted into pBShuMγG238, which encodes human Meltrin γ.

[0102]

FIG. 14

a
shows schematically the cloning region in the cloning of human Meltrin α.

[0103]

FIG. 14

b
shows schematically the cloning region in the cloning of human Meltrin β.

[0104]

FIG. 15

a
˜FIG. 15f show partial amino acid sequence and its corresponding base sequence of human Meltrin a,determined based on the result of analysis of the DNA inserted into pMelα-26N, pMelα-25C.

[0105]
FIG. 16 shows amino acid sequence and its corresponding base sequence of human Meltrin β.

[0106]

FIG. 17

a
˜FIG. 17c show partial amino acid sequence and its corresponding base sequence of human Meltrin β, determined based on the result of analysis of the DNA inserted into pMelβ-24C, pMelβ-24N.

[0107]

FIG. 18

a
shows schematically the sites of the peptides administered as the antigens in mouse Meltrin α.

[0108]

FIG. 18

b
shows amino acid sequences of the peptides administered as the antigens.

[0109]
FIG. 19 is a photograph of electrophoresis showing the result of Western blotting with anti-mouse Meltrin α antibodies.

[0110]
FIG. 20 is a graph showing the inhibition of myotube formation by anti-mouse Meltrin antibodies.

[0111]
FIG. 21 is a graph showing the effects by anti-mouse Meltrin antibodies on the formation of pit (bone-resorption area) by mouse all bone cells.

[0112]
FIG. 22 is a graph showing the effects on the serum Ca values of the mouse fed with low Ca-content feed by anti-mouse Meltrin antibodies.

[0113]

FIG. 23

a
˜FIG. 23b show the amino acid sequence comprising the transmembrane domain of human Meltrin α and its corresponding base sequence.

[0114]

FIG. 24

a
˜FIG. 24e show the result of base sequence analysis of the DNA inserted into pMelβ-24C, pMelβ-24N.

BEST MODE FOR CARRYING OUT THE INVENTION

[0115] The present invention will be further illustrated by the following Examples, which should not be construed to limit the scope of the present invention.

EXAMPLE

[0116] The abbreviations used in the following description are based on the conventional ones in the art.

[0117] The processes used in the following Examples are based on Sambrook J. et al., Molecular Cloning, a Laboratory Manual 2nd ed., Cold Spring Harbor Laboratory, New York, 1989; E. Harlow, D. Lane et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; and the like.

Example 1

[0118] Acquisition of the DNAs Encoding Mouse Meltrins by RT-PCR

[0119] 1 Preparation of RNA, cDNA

[0120] A myogenic cell line derived from fetal fibroblast C3H10T1/2, (a clone transfected by the gene encoding “myogenin”, a muscle differentiation-controlling factor and expressing the myogenin) was proliferated to the extent of 106 cells/φ 10 cm plate in DMEM supplemented with 10% fetal bovine serum (Moregate), and cultured at 37° C. for 2 days in differentiation medium (DMEM containing 2% horse serum from GIBCO) for differentiation and inducation. Total RNA was separated according to the Guanidine isothiocyanate/acid phenol method (Chomczynski P. and Sacchi N., Anal. Biochem., 162, 156-159, 1987), and poly (A) RNA was selectively separated by repeating twice oligo(dT)-cellulose column chromatography. By using the poly(A) RNA as a template and random primers (N6, Pharmacia), cDNAs were synthesized with MLV reverse transcriptase (GIBCO BRL) according to its manual for synthesis. The obtained cDNAs were then used as a template for the next PCR, and double strand DNAs were synthesized and inserted into a phage (λZapII(stratagene)) to give a cDNA library.

[0121] (2) RT-PCR

[0122] RT-PCR was carried out by using the cDNAs prepared in the above (1) as a template in the following steps:

[0123] A degenerative primer encoding the amino acid sequence EDCDCG or EECDCG was synthesized and used as a sense primer, and a degenerative primer encoding the amino acid sequence KCGKLIC was synthesized and used as an antisense primer.

[0124] The primers were mixed with the above cDNAs, Taq polymerase and the reaction agents (Boehringer Manheim), and subjected to 36 reaction cycles of 95° C. for 1 min, 55° C. for 2 min, and 72° C. for 3 min. The amplification product of around 450 bp was then collected by 1.5% agarose gel electrophoresis.

[0125] The amplified fragments thus obtained were inserted into a SmaI site in the plasmid pBS-SKII(−) (stratagene), and subjected to DNA sequence analysis by means of a DNA sequencer (370A type, Applied Biosystems). As a result, it was found that three kinds of molecules (DNA fragments) existed (FIG. 1), which were then used as a probe to screen the cDNA library so as to isolate cDNAs comprising an open reading frame with 903, 920 and 845 amino acid residues, respectively (FIG. 2a˜FIG. 2j, FIG. 3a˜FIG. 3j, FIG. 4a˜FIG. 4i). The products of the respective genes were named Meltrins α, β, and γ (FIG. 5a˜FIG. 5j, FIG. 6a˜FIG. 6h, FIG. 7a˜FIG. 7e). These cDNAs were inserted into pBS-SKII(−) to give the plasmids, “pBSMelα”, “pBSMelβ”, and “pBSMelγ”, respectively.

[0126]

E.coli
strain JM109 was transformed according to a known method by the above plasmids “pBSMelα”, “pBSMelβ”, and “pBSMelγ”, respectively, and the resulting transformants “JM109(pBSMelα)”, “JM109(pBSMelβ)”, and “JM109(pBSMelγ)” were deposited in the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken 350 Japan) on Feb. 19, 1996 under accession numbers FERM P-15451, FERM P-15452, and FERM P-15453, respectively, and then transferred on Oct. 8, 1996 to the deposit under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and Regulation under accession numbers FERM BP-5701, FERM BP-5702, and FERM BP-5703, respectively.

[0127] (3) Analysis of the Structure of Meltrins

[0128] From the structure analysis of Meltrins on the basis of the DNA sequences determined in the above (2), it was supposed that Meltrins α, β, and γ were a transmembrane-type protein consisting of an extracellular domain, transmembrane (TM) domain, and intracellular domain, and that the extracellular domain consists of a precursor domain (pro region) comprising a signal peptide-like sequence, metalloproteinase domain, disintegrin domain, and the following cysteine-rich region. A fusion peptide-like sequence was contained in the cysteine-rich domain of Meltrin a (FIG. 8).

[0129] Based on their homology to the snake venom, Jararhagin, it has been considered that in Meltrin a,the precursor domain corresponded to the sequence from N-terminal to Arg (No.205) and to the bases No.221-835, the metalloproteinase domain to the sequence from Glu (No.206) to Pro (No.414) and to the bases No.836-1462, the disintegrin domain to the sequence from Phe (No.420) to Gly (No.509) and to the bases No.1478-1747, the cysteine-rich region to the sequence from His (No.510) to Gly (No.706) and to the bases No.1748-2338, the fusion peptide-like sequence to the sequence from Gly (No.585) to Glu (No.607) and to the bases No.1973-2041, the transmembrane domain to the sequence from Leu (No.707) to Leu (No.727) and to the bases No.2339-2401.

[0130] Similarly, it was considered that in Meltrin β, the precursor domain corresponded to the sequence from N-terminal to Arg (No.204) and to the bases No.63-674, the metalloproteinase domain to the sequence from Glu (No.205) to Pro (No.409) and to the bases No.675-1289, the disintegrin domain to the sequence from Tyr (No.415) to Gly (No.504) and to the bases No.1305-1574, the cysteine-rich region to the sequence from Thr (No.505) to Pro (No.706) and to the bases No.1575-2180, the transmembrane domain to the sequence from Val (No.707) to Arg (No.729) or to Leu (No.724) and to the bases No.2181-2249 or 2181-2234.

[0131] Similarly, it was considered that in Meltrin γ, the precursor domain corresponded to the sequence from N-terminal to Arg (No.205) and to the bases No.69-683, the metalloproteinase domain to the sequence from Ala (No.206) to Pro (No.406) and to the bases No.684-1292, the disintegrin domain to the sequence from Tyr (No.412) to Gly (No.502) and to the bases No.1302-1574, the cysteine-rich region to the sequence from Tyr (No.503) to Ala (No.694) and to the bases No.1575-2150, the transmembrane domain to the sequence from Leu (No.695) to Ile (No.714) and to the bases No.2151-2210.

Example 1

[0132] Establishment of Anti-Meltrin α Antibodies

[0133] (1)Preparation of Immunogen

[0134] A chimera polypeptide was prepared as follows, which consisted of glutathione-S-transferase (GST) (Smith, D. B. & Johnson, K. S., Gene, Vol.67, 31-40, 1988) and the polypeptide having the amino acid sequence from Ser. (No.483) to Lys (No.635) of Meltrin α in FIG. 2a˜FIG. 2j, said polypeptide being attached to the C-terminal of GST. First, the plasmid, pGEX2T (Pharmacia) comprising the cDNA encoding GST was digested at a BamHI site and used as a vector. On the other hand, the cDNA corresponding to the amino acid sequence from Ser. (No.483) to Lys (No.635) of Meltrin α in FIG. 2a˜FIG. 2j was amplified from pBSMelα by PCR, and ligated with a BamHI linker by a DNA ligase. The resulting cDNA was then ligated with the above vector by a DNA ligase to give a plasmid, which was then tranformed into E.coli strain NM522.

[0135] The transformed E.coli was cultured in L-broth with 1 mM IPTG to produce a large amount of the chimera polypeptide in the inclusion bodies upon expression-induction. The strain was suspended into MTPBS (150 mM NaCl, 16 mM Na2HPO4, 4 mM NaH2PO4, 0.1 mM PMSF), subjected to ultrasonication, and solubilized with 1% Triton. The supernatant of the thus treated mixture was collected. Glutathione agarose (Sigma) was mixed with the supernatant to adsorb the chimera polypeptide which was then eluted with an elution buffer (50 mM Tris-HCl, pH 8.0, 0.5 mM glutathione) and used as an immunogen.

[0136] (2) Preparation of Antiserum

[0137] The antigen (1 mg) prepared in the above (1) in 0.5 ml PBS and RIBI in PBS 0.5 ml (MPL+TDM+CWS Emulsion, Funakoshi) were mixed with each other, and subcutaneously or intracutaneously administered into a rabbit (12 weeks old, female). After boosting three times with 500 μg dose at 4 week intervals, the blood was collected and serum was separated to give antiserum.

[0138] (3) Affinity Purification of Antiserum

[0139] The chimera polypeptide expressed in E.coli and solubilized in the above (1), or GST having no fused polypeptide was bound to the glutathione agarose beads. The resulting beads were washed with 0.2 M sodium borate (pH 9.0), and mixed with dimethyl pimelidiate (a final concentration of 20 mM) so that the antigen was irreversibly bound to the beads, so as to give chimera polypeptide-affinity beads and GST-affinity beads, respectively.

[0140] The antiserum diluted ten times with 10 mM Tris-HCl (pH 7.5) was first mixed with the GST-affinity beads for anti-GST antibodies to be absorbed and removed, and then mixed with chimera polypeptide-affinity beads for anti-Meltrin α antibodies to be adsorbed thereon. The resulting chimera polypeptide-affinity beads were washed with 10 mM Tris (pH 7.5) and 500 mM NaCl, and the anti-Meltrin α antibodies were eluted with 100 mM glycine and collected as purified anti-Meltrin α antibodies.

[0141] (4) Western Blotting

[0142] C2 cell was proliferated to the extent of 106 cells/φ 10 cm plate in DMEM supplemented with 15% fetal bovine serum, then cultured at 37° C. in differentiation medium (DMEM supplemented with 2% horse serum) and collected on the second day (C2DM d2) and on the 4th day (C2DM d4).

[0143] Further, C2 cell transformed by pBOSMelα (+) prepared in the following Example 5 (3) was cultured in DMEM supplemented with 15% fetal bovine serum at 37 ° C. for three days, inoculated into a plastic dish (φ 6 cm) at a density of 2×105/dish, further cultured for one day and transferred into the above differentiation medium for differentiation induction. After two day-culture in the differentiation medium, the cells were collected.

[0144] The collected C2DM d2, C2DM d4 or transformants by pBOSMela (+) were mixed with SDS solubilizing buffer (100 mM Tris-HCl (pH 6.8), 4% SDS, 20% Glycerol), subjected to ultrasonication and centrifuged to give their supernatant as a sample. The sample were mixed with an equiamount of a gel loading buffer, supplied to SDS-PAGE, and electrophoresed. After the electrophoresis was finished, the contents were transferred to a membrane.

[0145] A membrane was washed twice with a washing solution. The antiserum prepared in the above (3) was diluted 20 times with 5% skim milk solution in TBS-T, into which the membrane was soaked and incubated at 37° C. for one hour. After the incubation, the membrane was washed twice with the washing solution. The membrane was then soaked into a biotin-labelled anti-rabbit immunoglobulin antibody (Daco) diluted 4,000 times with the above skim milk solution and incubated at 37° C. for one hour. After the incubation, the membrane was washed twice with the washing solution. The membrane was reacted with a peroxidase-labelled streptoavidin for one hour, washed twice, and detected by ECL system (Amersham).

[0146] The results are shown in FIG. 9.

[0147] The Western blotting revealed the bands at about 115 KD, 86 KD, 67 KD, and 58 KD, indicating that Meltrin α was expressed as a glycoprotein. It was also considered that the precursor domain was deleted in the molecule of 86 KD, and both the precursor and metalloproteinase domains were deleted in the molecule of 67 KD or 56 KD.

Example 3

[0148] Northern Blotting

[0149] Poly (A)+ RNAs were prepared from various tissues of mouse (bone, brain, liver, heart and skeletal muscle of adult mouse; bone and skeletal muscle of newborn mouse; and bone and skeletal muscle of fetal mouse) by using a mRNA purification kit of Pharmacia according to the method described in Example 1. RNAs were denatured by heating at 65° C. for 5 min in 50% formamide, subjected to elecrtophoresis on 1.5% agarose gel comprising 6.6% formalin, and transferred onto a nylon membrane (Highbond-N, Amersham).

[0150] On the other hand, cDNAs encoding a part of the disintegrin and cysteine-rich regions (Glu(No.434)-Cys(No.583) in FIG. 2a˜FIG. 2j, Clu(No.429)-Cys(No.578) in FIG. 3a˜FIG. 3j, Glu(No.426)-Cys(No.575) in FIG. 4a˜FIG. 4i) were prepared by PCR, and labelled with 32P using a random primer labelling kit (Megaprime, Amersham). As a control probe, cDNA encoding G3PDH (glyceraldehyde 3-phosphate dehydrogenase) was also labelled with 32P in the same way. The above mRNAs were hybridized with the radiolabelled cDNAs under high stringency conditions according to the method of Sambrook J.et al. (Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Habor Laboratory, New York, 1989).

[0151] Their results are shown in FIG. 10.

[0152]
FIG. 10 has revealed that Meltrin α and β were expressed only in bones of adult and newborn mice, and skeletal muscles of newborn and fetal mouses (the results from the fetal mouse are not shown in FIG. 10). There was no tissue-specificity in the expression of Meltrin β, since it was universally expressed in all the tissues.

Example 4

[0153] Confirmation of Adhering Activity of Meltrin α

[0154] (1) Construction of Plasmids pBOSMelαδMP(+) and pBOSMelαδMP(−)

[0155] A deletion type Meltrin δMP wherein the precursor and metalloproteinase domains in the extracellualr domain of Meltrin α had been deleted was prepared in the followig method.

[0156] The plasmid, pBSMelα was partially digested at MscI and subjected to electrophresis on 1% agarose gel to give a linear plasmid DNA. The resulting DNA was partially digested at NheI, treated with a Klenow fragment to generate blunt ends, and subjected to intramolecular ligation. Vectors having the right deletion were selected and their DNA sequences were confirmed. After digestion at multicloning sites of EcoRV and NotI in the vectors, a deletion type δMP fragment of about 5.8 kb was obtained.

[0157] On the other hand, the plasmid, pEFBOS (Mizushima S. & Nagata S, Nucleic Acid Res. Vol.18, p.5322, 1990) was digested by a restriction enzyme XbaI, dephosphorylated, treated with a Klenow fragment to generate blunt ends and subjected to electrophresis on 1% agarose gel to give a linear plasmid DNA. The resulting linear DNA was then ligated with the above fragment of about 5.8 kb by a DNA ligase to give the plasmids pBOSMelαδMP(+) and pBOSMelαδMP(−). They were the constructs comprising the inserted DNA encoding the δMP fragment wherein the amino acid sequence of from Ile(55) to Glu(399) of Meltrin α was deleted, in sense direction and antisense direction, respectively.

[0158] (2) Construction of Plasmid pBOSMelα(+)

[0159] The plasmid, pBSMelα, was partially digested by EcoRV and NotI to give a fragment of about 7 kb. The above pEFBOS plasmid was digested by a restriction enzyme XbaI, dephosphorylated, treated with a Klenow fragment to generate blunt ends, and subjected to electrophresis on 1% agarose gel to give a linear plasmid DNA. The resulting linear DNA was then ligated with the above fragment of about 7 kb by a DNA ligase to give the plasmids pBOSMelα(+).

[0160] (3) Preparation of Plasmid pBOSMelαδPro(+)

[0161] There was a AflII site in the boundary region between the precursor and metalloproteinase domains of Meltrin α, and there was a NheI site in the boundary region between metalloproteinase and disintegrin domains of Meltrin α. On the other hand, there remained the NheI site in the boundary region between the signal peptide-like sequence and disintegrin domain in pBOSMelαδMP(+) prepared in the above (1). Accordingly, pBOSMelα was digested at AflII, ligated with a NheI linker immediately before its metalloproteinase domain and digested at NheI, so that the metalloproteinase would be excised. The excised domain was inserted into the NheI site between the signal peptide-like sequence and the disintegrin domain of pBOSMelαδMP(+) to give the expression plasmid, pBOSMelαδPro(+) encoding δPro wherein there a deletion was found around the precursor domain (the amino acid sequence of from Ile(No.55) to Glu(No.206) of Meltrin α).

[0162] (4) Confirmation of Myoblast Fusion-Promoting Activity

[0163] Myoblast cell line C2 was transfected by the mixture comprising the plasmid pBOSMelα(+) or pBOSMelαδMP(+), and the plasmid pSV2NEO in a molar ratio of 20:1 by using LIPOFECTAMINE (Gibco BRL) according to its protocol. The transfected cells were diluted and inoculated on a plate (φ 10 cm) coated with collagen (IWAKI) so that the transformants would be obtained at a density of 10-20 clones per plate. The inoculated cells were cultured for 12 days in DMEM containing 20% fetal bovine serum and 5 ng/ml of bFGF (Gibco BRL) followed by isolation thereof.

[0164] For the purpose of the examination of myoblast fusion-promoting activity, the resulting transformants and the parent strain C2 were cultured for 3-4 days in the absence of bFGF, inoculated onto a plastic dish (φ 6 cm) at a density of 2×105/dish, and further cultured for one day, followed by the 4 day culture in the above differentiation medium for differentiation induction. Upon differentiation induction, C2 began to form myotubes. After the 4 day culture followed by fixation with methnol and staining with Giemsa and Wright's reagents (Merck), the number of nuclei were determined at any four independent fields of 1 mm2 on the dish and fusion index was calculated as follows:

Fusion Index =100*(The number of nuclei in multicleate syncytium having three or more nuclei)/(The number of the total nuclei)

[0165] Further, the time course of the fusion index was observed after differentiation induction every one day for five days.

[0166] The results are shown in FIG. 11a˜FIG. 11b. As seen from these figures, the fusion activity of the transformant expressing the full length of Meltrin α (pBOSMelα(+) which was referred to as “full length” in FIG. 11a) become lower than that of the parent cell, and it was therefore considered that the full length of Meltrin α would suppress the cell fusion in some way. On the other hand, the transfomant harboring pBOSMelαδMP(+), which was referred to as “ΔMP” in the figures, significantly promoted the cell fusion activity. It was also observed that the transformant harboring pBOSMelαδPro(+) promoted the cell fusion activity.

[0167] On the other hand, the C2 cell transformed by the plasmid pBOSMelβ(+) prepared by the insertion of the DNA encoding the full length of Meltrin β in the same way as in the above (2) could not cause any significant change in the fusion activity for muscle cells. However, The C2 transformant cotransfected by pBOSMelα(+) and pBOSMelβ(+) promoted the cell fusion activity compared with that of parent cell.

[0168] On the other hand, neither the C2 cell transformed by the plasmid pBOSMelγ(+) prepared by the insertion of the DNA encoding the full length of Meltrin y in the same way as in the above (2), nor the C2 transformant cotransfected by pBOSMelα(+) and pBOSMelγ(+) could cause any significant change in the fusion activity for muscle cells.

[0169] These results demonstrate that Meltrin α is involved in the fusion of muscle cells, and will show its activity to promote the cell fusion upon its processing. It is estimated that Meltrin α or Meltrin β does not act alone, but act in the form of a heteromer between them, since the transformant expressing both Meltrin α and Meltrin β promoted the fusion of muscle cells.

[0170] (5) Examination of the Function of Meltrins in Non-muscle Cells

[0171] The mouse fibroblast L929 was transformed by pBOSMelα(+) or pBOSMelβ(+) and the transformants expressing Meltrin α or Meltrin β were isolated. These transformants did not aggregate, nor fuse with each other. This was also true for the case of the transformant expressing both Meltrin α and Meltrin β.

[0172] On the other hand, the L929 cells transformed by pBOSMelγ(+) could showed a significant aggregation activity upon the addition of calcium ion, after the cells had been torn from a plate in a medium comprising no calcium ion.

[0173] These results demonstrate that Meltrin γ has a cell aggregation activity, and by considering the similarity of these molecules it is suggested that myoblast fusion-promoting activity of Meltrin α and Meltrin β may be attributed to their myoblast aggregation-promoting activity.

Example 5

[0174] Inhibition of Adhering Activity by Antisense

[0175] The plasmid BOSMelαδMP(−) prepared in Example 4 (1) was mixed with the plasmid PSV2NEO at a molar ratio of 20:1, by which C2 cells were tranformed according to the method of Example 4 (4) followed by isolation of the transformants expressing antisense RNA. The adhering activity of the thus isolated transfomants was determined by the method of Example 4. The results are shown in FIG. 11a˜FIG. 11b, which demonstrated that the fusion of C2 cells was inhibited by the expression of antisense RNA for δMP (referred to as “AS” in the figures).

[0176] The above results have revealed that Meltrin α plays an essential role in the cell fusion of muscle cells.

Example 6

[0177] Preparation of cDNA Fragments Encoding Human Meltrins α and γ

[0178] By using mRNA purified from human myelocytes (Clonetech Co.) as a template, cDNAs were prepared according to the method of Example 1 (1), and 36 cycles of PCR was then carried out by using the degenerative primer obtained in Example 1 (2) and said cDNAs as a template. The amplified product was inserted into a EcoRV site of pBS-SKII(−), and named “pBShuMα300.” The results of DNA sequencing are shown in FIG. 12a and FIG. 12b.

[0179] It was found that the DNA sequence comprised the base sequence encoding the part from an intermediate position of the disintegrin domain to an intermediate position of the cysteine-rich region of human Meltrin α (the disintegrin domain is located to Gly (No.36), followed by the cysteine-rich region in FIG. 12a and FIG. 12b).

[0180] On the other hand, by using a part of a human sequence (D-14665) registered with a data base, whose function had not yet identified, a senseprimer (5′-CACGATGATGGGAGAGATTG-3′) and antisense primer (3′-CACTCTGATTTCCTATGCCTC-5′) were synthesized. PCR was carried out according to the above method to give the amplified product, which was then inserted into the EcoRV site of pBS-SKII(−), and named “pBShuMγG238.” The results of DNA sequencing are shown in FIG. 13a and FIG. 13b.

[0181] It was found that the DNA sequence comprised the base sequence encoding the part from an intermediate position of the metalloproteinase domain to an intermediate position of the cysteine-rich region of human Meltrin γ (the metalloproteinase domain is located from N-termial to Pro (No.40), the disintegrin domain from Lys (No.41) to Gly (No.136) or from Tyr (No.46) to Gly (No.136), followed by the cysteine-rich region from Tyr (No.137)). The E. coli strain JM109 was transfomed by those plasmids to give JM109(pBShuMα300) and JM109(pBShuMγG238), which were deposited in the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken 350 Japan) on Feb. 19, 1996 under accession numbers FERM P-15454 and 15455, respectively, and then transferred on Oct. 8, 1996 to the deposit under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and Regulation under accession numbers FERM BP-5704 and 5705, respectively.

Example 7

[0182] Preparation of cDNA Fragment Encoding Human Meltrin α by Usig cDNA Library Derived from Human Placenta-1

[0183] (1) First Screening

[0184] Based on the cDNA sequence of Meltrin α obtained in Example 6, sense primer MA-1 and antisense primer MA-2 were synthersized (see Table 1). The human placenta λgtll cDNA library (Clonetech Co., code No. CLHL1008b) was inoculated onto LB plate (φ 10 cm) at such a density that 10,000 plaques per plate may be obtained. After the formation of plaques, SM buffer 5 ml was added to each plate, the plates were put by incubation at a room temperature for 4 hours, and phages were collected from each plate (plate lysate method). PCR was carried out by using the collected phage solution as a template. Thus, MA-1 and MA-2 primers, Ex Taq polymerase (TaKaRa Co.,), and its reagents (TaKaRa Co.,) were mixed, followed by 35 cycles of the reactions at 94° C. for 30 sec, 55° C. for 30sec, and 72° C. for one min. A part of the amplified products was subjected to an agarose gel electrophoresis, and a phage solution of the clone comprising Meltrin α cDNA was selected.

[0185] (2) Second Screening

[0186] The phage solution of the desired clone obtained in the first screening was inoculated at such a density that 400 plaques per plate may be obtained. After the formation of plaques, phages were collected in the same manner as above and a phage solution comprising the desired clone was selected.

[0187] (3) Third Screening

[0188] The phage solution of the desired clone obtained in the second screening was inoculated at such a density that 40 plaques per plate may be obtained. After the formation of plaques, phages were collected in the same manner as above and a phage solution comprising the desired clone was selected.

[0189] (4) Forth Screening

[0190] The phage solution of the desired clone obtained in the third screening was inoculated at such a density that 10 plaques per plate may be obtained. After the formation of plaques, phages were collected in the same manner as above and a phage solution comprising the desired clone was selected.

[0191] (5) Final Screening

[0192] The phage solution of the desired clone obtained in the forth screening was inoculated at such a density that 20 plaques per plate may be obtained. After the formation of plaques, each plaque was stuck with a toothpick, and the sticking material was suspended as a template into PCR solution. The above 35 cycles of the PCR with MA-1 and MA-2 primers finally gave two psitive clones. A single positive plaque comprising the desired clone was collected in SM buffer, and the phage was lysed thereinto.

[0193] PCR was carried out by using λgtll Forward primer and λgtll Reverse primer (Table 1) to give a fragment of human Meltrin α cDNA in the phage vector.

[0194] From a partial DNA sequencing of the terminal bases of the resulting fragments it was estimated that those cDNAs comprised the base sequences encoding human Meltrin α obtained in Example 6, and corresponded to about 650 amino acids (Clone 23) or about 500 amino acids (Clone 25) of mouse Meltrin (FIG. 14).

Example 8

[0195] Preparation of cDNA Fragment Encoding Human Meltrin α by Usig cDNA Library Derived from Human Placenta-2

[0196] A sense primer Mel α-5′S was designed based on the sequence encoding the N-terminal of the cDNA sequence of the clone 23 revealed in Example 7. The human placenta λgtll cDNA library (Clonetech Co.) was screened by the sense primer Mel α-5′S and antisense primer MA-2 to give cDNA encoding about 700 amino acids (Clone 26) (FIG. 14a). For the purpose of the analysis of the base sequence of Meltrin gene, the four primers, λgtll Forward-Eco, λgtll Reverse-Eco, MA-1-Eco, and MA-2-Eco were synthesized (Table 1).

1TABLE 1The base sequences of the primers for PCRMA-1:5′ ACG ATG GGC ACT CAT GTC AG 3′MA-2:5′ CAT CTC GCA TTT GGC AAA GG 3′λ gtll Forward:5′ GGT GGC GAC GAC TCC TGG AGC CCG 3′λgtll Reverse:5′ TTG ACA CCA GAC CAA CTG GTA ATG 3′Mel α-5′S:5′ CAC TGA ACA TTC GGA TCG TG 3′λ gtll Forward-Eco:5′ CCG GAA TTC GGT GGC GAC GAC TCC TGG AGC CCG 3′λ gtll Reverse-Eco:5′ CCG GAA TTC TTG ACA CCA GAC CAA CTG GTA ATG 3′MA-1-Eco:5′ CCG GAA TTC ACG ATG GGC ACT CAT GTC AG 3′MA-2-Eco:5′ CCG GAA TTC CAT CTC GCA TTT GGC AAA GG 3′S-hMel α-TM5′:5′ GCA CAA AGT GTG CAG ATG GAA-mMel α-3′:5′ CAG AGG CTT CTG AGG AGG N

[0197] The second half of the Meltrin gene was amplified by PCR using Clone 25 as a template, and MA-1-Eco and λgtll Reverse-Eco primers. The first half of the Meltrin gene was amplified by PCR using Clone 26 as a template, and MA-2-Eco and λgtll Forward-Eco primers. These cDNA fragments were digested at EcoRI and cloned into the EcoRI site of pUC 118 to give the plasmid vectors “pMelα-26N” and “pMelα-25C”, respectively. The sequences of Meltrin α cDNA comprised in these plasmids were determined by a conventional method.

[0198] The E.coli strain JM109 was transfomed by those plasmids according to the known method of Hanahan et al. to give JM109(pMelα-26N) and JM109(pMelα-25C), and were deposited in the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken 350 Japan) on Oct. 3, 1996 under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and Regulation under accession numbers FERM BP-5689 and 5688, respectively.

[0199] The base sequence and its corresponding amino acid sequence of human Meltrin α which had been revealed by the base sequencing of pMelα-26N and pMelα-25C are shown in FIG. 15a˜FIG. 15f.

[0200] Comparison of the DNA sequence thus obtained with that obtained in Example 6 indicated four discrepancies in base pairs, the three of which being silent mutation, and the other discrepancy causing substitution of Asp (No.505) in the above figures for Glu in the sequence of Example 6.

[0201] The analysis of the structure of the base sequence showed that the DNA encoded the sequence from an intermediate part of the precursor domain to the C-terminal of Meltrin α. Thus, it has been considered that in the amino acid sequence shown in FIG. 15a˜FIG. 15f, the partial sequence (C-terminal) of the precursor domain corresponds to the the sequence from Gly N-terminal to Arg (No.155) and to the bases No.1-465, the metalloproteinase domain to the sequence from Glu (No.156) to Pro (No.364) and to the bases No.466-1092, the disintegrin domain to the sequence from Glu (No.365) or Phe (No.370) to Gly (No.459) and to the bases No.1093 or 1108-1377, the cysteine-rich region to the sequence from His (No.460) to Gln (No.656) or Ala (No.652) and to the bases No.1378-1968 or 1956, the fusion peptide-like sequence to the sequence from Gly (No.535) to Gln (No.557) and to the bases No.1603-1671. There was no transmembrane domain in this sequence, suggesting that human Meltrin α existed as a soluble protein without a transmembrane domain in a body. In other words, it is considered that Meltrin α having the amino acid sequence of FIG. 15a˜FIG. 15fis extracellularly secreted and present in blood or body fluid. It is considered that such soluble Meltrin α takes a part in regulating adhesion, fusion and aggregation of cells in the body.

[0202] It is considered that Meltrin α having the amino acid sequence of FIG. 15a˜FIG. 15fhas generated as a result of an alternative splicing of the gene. It is also considered that the DNA encoding the region downstream of the cysteine-rich region, and the DNA encoding transmembrane domain and intracellular domain are located on different exons, and that the splicing out of either DNA would yield a soluble type Meltrin, or a membrane-binding type Meltrin.

Example 9

[0203] Preparation of cDNA Fragments Encoding Human Meltrins β

[0204] (1) Preparation of cDNA Fragment Encoding a Part of the Disintegrin Domain of Human Meltrin β

[0205] By using mRNA purified from human myelocytes (Clonetech Co.) as a template, cDNAs were prepared according to the method of Example 1 (1), and 36 cycles of PCR were then carried out by using the degenerative primers obtained in Example 1 (2) and said cDNAs as a template. The amplified product was inserted into pBS-SKII(−). The analysis of the resulting DNA sequence revealed that it was a partial sequence of Meltrin β. The determined DNA sequence is shown in FIG. 16.

[0206] (2) First Screening by Using cDNA Library Originated in Human Fetal Lung

[0207] Based on the partial cDNA sequence of Meltrin β obtained in the above (1), sense primer MA-3 and antisense primer MA-4 were synthersized (see Table 2). The human fetal lung λgtll cDNA library (Clonetech Co., code No. CLHL1072) was inoculated onto LB plate (φ 10 cm) at such a density that 10,000 plaques per plate may be obtained. After the formation of plaques, SM buffer 5 ml was added to each plate. And the plates were put at a room temperature for 4 hours, and phages were collected from each plate (plate lysate method). PCR was carried out by using the collected phage solution as a template. Thus, MA-3 and MA-4 primers, Ex Taq polymerase (TaKaRa Co.,), and its reagents (TaKaRa Co.,) were mixed, followed by 35 cycles of the reactions at 94° C. for 30 sec, 55° C. for 30 sec, and 72° C. for one min by means of DNA thermal cycler (Perkin Elmer Co.,). A part of the amplified products was subjected to an agarose gel electrophoresis, and a phage solution of the clone comprising Meltrin β cDNA was selected.

[0208] (3) Second Screening

[0209] The phage solution of the desired clone obtained in the first screening was inoculated at such a density that 1000 plaques per plate may be obtained. After the formation of plaques, phages were collected in the same manner as above and a phage solution comprising the desired clone was selected.

[0210] (4) Third Screening

[0211] The phage solution of the desired clone obtained in the second screening was inoculated at such a density that 100 plaques per plate may be obtained. After the formation of plaques, phages were collected in the same manner as above and a phage solution comprising the desired clone was selected.

[0212] (5) Forth Screening

[0213] The phage solution of the desired clone obtained in the third screening was inoculated at such a density that 10 plaques per plate may be obtained. After the formation of plaques, phages were collected in the same manner as above and a phage solution comprising the desired clone was selected.

[0214] (6) Collection and Confirmation of DNA Fragment Comprising Partial cDNA Sequence

[0215] The PCR was carried out using the phage solution of the desired clone obtained in the forth screening (#24) as a template, and a combination of λgtll Forward primer (Table 1) and MA-4 primer or a combination of λgtll Reverse primer (Table 1) and MA-3 primer to give amplified products with about 500 bp (24-F/4) and about 5 kbp (24-R/3), respectively. From a partial DNA sequencing of the terminal bases of the resulting two DNA fragments, it was estimated that those cDNA comprised the base sequences determined in the above (1).

[0216] (7) Analysis of Base Sequences

[0217] For the purpose of subcloning of the cDNA fragments comprising the cDNA partial sequence of human Meltrin β, two primers MA-3-Eco and MA-4-Eco were newly synthersized (see Table 2).

[0218] The PCR was carried out using the phage solution (#24) as a template, and a combination of λgtll Forward-Eco primer (Table 1) and MA-4-Eco primer or a combination of λgtll Reverse-Eco primer (Table 1) and MA-3-Eco primer. The resulting amplified products were digested with EcoRI and inserted into the EcoRI site of pUC118 to give the plasmids, “pMelβ-24C” and “pMelβ-24N”, respectively. The sequence of Meltrin β cDNA comprised in these plasmids was determined by a conventional method.

[0219] The E. coli strain JM109 was transfomed by those plasmids according to the known method of Hanahan et al. to give JM109(pMelβ-24C) and JM109(pMelβ-24N), and were deposited in the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken 350 Japan) on Oct. 3, 1996 under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and Regulation under accession numbers FERM BP-5690 and 5691, respectively.

[0220] The base sequence and its corresponding amino acid sequence which had been revealed by the base sequencing of pMelβ-24C and pMelβ-24N are shown in FIG. 24a˜FIG. 24e.

[0221] Comparison of the DNA sequence thus obtained with that obtained in the above (1) showed one discrepancy in base pairs, which was a silent mutation, causing no change of amino acid.

[0222] The analysis of the structure of the base sequence showed that the DNA encoded the sequence from an intermediate part of the metalloproteinase domain to the C-terminal of human Meltrin-β. Thus, it has been considered that in the sequence shown in FIG. 24a˜FIG. 24e, the partial sequence at C-terminal of the metalloproteinase domain corresponds to the the sequence from Gly (N-terminal) to Pro (No.36) and to the bases No.2-109, the disintegrin domain to the sequence from Asp (No.37) or Tyr (No.42) to Gly (No.131) and to the bases No.110 or 125-394, the cysteine-rich region to the sequence from Thr (No.132) to Pro (No.330) and to the bases No.395-991, the transmembrane domain to the sequence from Val (No.331) to Met (No.348) or Arg (No.353) and to the bases No.992-1045 or 1060. It is considered that the sequence from Tyr (No.349) or Gln (No.354) corresponds to the intracellular domain. However, as homology analysis to mouse Meltrin β shows a very low homology in the sequence from Pro (No.395), it is estimated that the sequence up to His (No.394) is involved in the function of extracellular domain of human Meltrin β. The sequence up to Pro (No.395) in FIG. 24a˜FIG. 24e is shown in FIG. 17a˜FIG. 17c.

2TABLE 2The base sequences of the primers for PCRMA-3:5′ TGC TGC CAC CAG TGT AAG 3′MA-4:5′ TCC TGG TAG GTG AGG CAC ATG 3′MA-3-Eco:5′ CCG GAA TTC TGC TGC CAC CAG TGT AAG 3′MA-4-Eco:5′ CCG GAA TTC TCC TGG TAG GTG AGG CAC ATG 3′

Example 10

[0223] Preparation of Anti-Meltrin α Monoclonal Antibodies

[0224] (1) Selection of Peptides

[0225] Based on the amino acid sequence of mouse Meltrin α determined in Example 1, their epitopes were analysed.

[0226] Eight kinds of peptide sequences were selected as a potential epitope, based on the secondary structure estimated from the regions wherein discrepancy in amino acids is seen between Meltrins α and β, the estimated non-RGD region, and the region wherein metalloproteinase had been cleaved (FIG. 18a and b). These eight kinds of peptides were synthesized by Peptide Synthesizer (ABI 432A) so that they would have Cys at their C-terminal, cleaved, and purified by HPLC of a reverse phase column (YMC-ODS).

[0227] (2) Preparation of Antiserum

[0228] After lyophilization of the peptides obtained in the above (1), each peptide 0.55 mg was dissolved in 0.1 M phosphate buffer (pH 7.0) 55 μl. Maleimidated KLH (Boehringer Manheim) 0.77 mg was dissolved in distilled water 77 μl. The two resulting solutions were combined, and reacted at a room temperature for two hours, followed by the purification by Nick column (Pharmacia) equilibrated with physiological saline to give antigens to be used in the following experiments.

[0229] Each antigen 50 μg was diluted with physiological saline to 0.1 ml, mixed with the same amount of Freund's complete adjuvant (DIFCO) and administered intraperitoneally into Wistar rat (5 weeks old, female). The antigen was mixed with the same amount of Freund's incomplete adjuvant (DIFCO) and administered two weeks later in the same way as above.

[0230] (3) Evaluation of Antiserum (Plate Assay)

[0231] After one week from the administration, the blood was drawn from the eyeground of the rat, and an increase of the antibody titer for the administered peptides was confirmed by the reaction between immobilized peptides and the antiserum according to a plate assay as follows.

[0232] First, 50 mM phosphate buffered saline (0.9% NaCl, pH 7.2) comprising 0.5 mg/ml of Sulfo-SMCC (Pierce) was poured into each well of an amino plate (Sumitomo Bakelite). After incubation at 37° C. for 2 hours, the wells were washed five times with ion-exchanged water, and the above buffer comprising 0.5 μg/ml of each peptide was added. After incubation at 37° C. for one hour, the well were blocked by 0.076 M phosphate buffered saline (0.45% NaCl, pH 6.4), which will be referred to hereinafter as “PBS”, comprising 0.1% of BSA and 4 mg/ml of cysteamine. The blocking agent was removed, each antiserum diluted 1,000 to 100,000 times with PBS was added followed by incubation at 37° C. for one hour. After two repeats of washing of the wells with 0.9% NaCl comprising 0.005% Tween20, an anti-rat immunoglobulin abtibody labelled with peroxidase (Dako) and diluted with PBS comprising 10% rabbit serum was added to each well followed by incubation at 37° C. for one hour. Upon the completion of the reaction, the wells were washed five times with a washing liquid and two times with ion-exchanged water. And 0.1 M McIlvaine buffer (pH 5.0) comprising 3 mg/ml of o-phenylene diamine and 0.027% hydro peroxide was added and reacted for 5 min. The reaction was terminated by the addition of 1N HCl, and absorbance at 490 nm was measured. The results are shown in Table 3, in which (++) means a reactivity, and (+) means a week reactivity. action of antiserum with the peptide antigens

3TABLE 3Reaction of antiserum with the peptide antigenspeptide antigensReaction of Antiserum1 ProA++2 MP-A++3 MP-B++4 DC-A+5 DC-B+6 DC-C++7 DC-DN.D.8 DEA++N.D. (not determined)

[0233] (4) Evaluation of Antiserum (Western Blotting)

[0234] For the confirmation of the binding of the antiserum prepared in the above (2) to Meltrins, Western blotting was carried out.

[0235] Mouse myoblast C2 was transformed by pBOSMelαβPro(+) and pBOSMelβ(+), which will be referred to hereinafter as “#9-3”, and mouse myoblast C2 was transformed by pBOSMelαβMP(+), which will be referred to hereinafter as “#3-5.”

[0236] Transformed C2 cells of 1×107 cells were washed with PBS-(GIBCO BRL) and collected by centrifugation. The density of the collected cells was adjusted to 5×106 cells/ml, mixed with a proteolysis inhibitor, Cφ mplete (Boehringer Manheim) in amount of one 25th of the volume of the cell mixture, and mixed with SDS to a final concentration of 0.2%. After incubation at a room temperature for 30 min, the cells were subjected to sonication at 4° C. for 10 sec (1 sec×10), and centrifuged. The resulting supernatant was collected and used as a cell lysate. Another cell lysate was prepared from fibroblast L929 (ATCC No.CCL-1) in the same way, and used as a negative control.

[0237] The resulting cell lysate (10 μl) was mixed with an equiamount of a gel loading buffer (0.25 M Tris-HCl, 2% SDS, 30% Glycerol, 0.01% BPB(pH 6.8)), the resulting solution (6 μl) was applied to SDS-PAGE of 4˜20T % (Tefco), and electrophoresed under 25 mA at a room temperature for about one hour. After the completion of the electrophoresis, the contents were transferred to PVDF membrane (Millipore) under the conditions of 150 mA, 4° C. and 45min. The membrane was blocked by shaking in 4% skim milk (Meiji Milk Co.) at a room temperature for one hour, and each lane was cut. Each excised lane was soaked and shaken in antiserum (1 ml) diluted 500 times with 50 mM Tris-HCl (pH 7.2) comprising 0.05% Tween20 (referred to hereinafter as “T-TBS”) and 4% skim milk at a room temperature for one hour. After the completion of the reaction, each lane was washed two times with T-PBS, soaked in lml of an anti-rat immunoglobulins antibody labelled with HRPO (Dako) diluted 500 times with T-PBS comprising 4% skim milk, and reacted at a room temperature for one hour. After washing five times with T-PBS, it was detected by ECL system (Amersham). The results are shown in Table 4. Bands were detected in the three kinds of the antiserums by the Western blotting.

4TABLE 4Reaction of antiserum with the cell lysate in Western blottingPeptide antigensWestern blotting1 ProA+2 MP-A−3 MP-B−4 DC-AN.D.5 DC-BN.D.6 DC-C+7 DC-DN.D.8 DEA+N.D. (not determined)

[0238] (5) Preparation of Monoclonal Antibody

[0239] The antigens (ProA, MP-B, DC-C, DEA) (50 μg each) were diluted with 400 μl of physiological saline, and injected into the tail vein of the rats whose antibody titer had increased. Three days later, cell fusion was carried out by using myeloma P3X63Ag8U.1 according to the known method (Monoclonal antibody Jikken Sosa Nyumon (Guide of monoclonal antibody preparation), Tamie Ando and Jo Chiba, Koudan-sha Scientific). Six days later, the culture supernatant was collected and subjected to the plate assay according to the method of the above (3). The wells that showed reactivity with the peptide antigens were subjected to cloning by limiting dilution(Monoclonal antibody Jikken Sosa Nyumon (Guide of monoclonal antibody preparation), Tamie Ando and Jo Chiba, Koudan-sha Scientific). After cloning, the screening by the plate assay was performed again to give 27 clones of the hybridomas producing an anti-mouse Meltrin a monoclonal antibody which reacted with the peptide antigens. The results are shown in Table 5.

5TABLE 5Hybridomas producing anti-Meltrin peptides monoclonal antibodyPeptide antigensHybridoma No.The number of HbProAF93610MP-BF939 4DC-CF933 4DEAF934 8

[0240] Purified antibodies were obtained from the thus established anti-Meltrin monoclonal antibody-producing hybridoma cell lines by the following method.

[0241] The hybridomas were cultured in RPMI1640 supplemented with 10% fetal bovine serum and 1 ng/ml of human IL6 till a final density of 2 ×105 cells/ml. The medium was then exchanged with a serum-free medium (Hybridoma-SFM, GIBCO BRL), and the culture was continued until the cells died. The resulting culture supernatant was filtered through filter paper for the removal of the cells, and subjected to purification by Protein G column (Prosep-G, Bioprocessing INC) as follows. The culture supernatant (1 L) was applied to Prosep-G column (20 ml) at a flow rate of 10 ml/min, followed by washing with 0.1 M phosphate buffer (pH 7.5) comprising 0.15 M NaCl. After the absorbance at 280 nm had decreased, the bound monoclonal antibody was eluted by 0.1 M citric acid buffer (pH 3.0). After neutralization of the pH, the eluate was concentrated with DIAFLO (Grace Japan), and dialysed against 0.076 M phosphate buffered saline (pH 6.4) comprising 0.45% NaCl. The concentration of the purified antibody was calculated on the basis of the absorbance at 280 nm.

[0242] (6) Evaluation of Monoconal Antibody

[0243] The binding activity of 7 lots of the purified antibodies (10 μg/ml each) obtained in the above (5) to Meltrin was confirmed by Western blotting according to the method of the above (4) using the cell lysate of #9-3 cell. The results are shown in FIG. 19. The band of about 67 kDa specific to the cell lysate of #9-3 cell was detected by the reaction with F933-4-3 (subclass IgG2a), F933-10-26 (subclass IgG2a), F934-17-6 (subclass IgG2a), F934-3-23 (subclass IgG2a), F934-4-33 (subclass IgG2a), F934-6-3 (subclass IgG2a), and F934-20-5 (subclass IgG2c). As these bands were not detected in the case of the cell lysate of L929 cell, it was confirmed that the monoclonal antibodies obtained in the above (5) were bound to Meltrin.

Example 11

[0244] Preparation of Anti-mouse Meltrin Monoclonal Antibody

[0245] (1) Preparation of the Antigen to be Adminitered and Immunization of Rat

[0246] Rats were immunized with #9-3 and #3-5 cells as the antigen to be administered as follows. The cells used as the antigen to be administered were cultured in the absence of bFGF. First, the cells cultured in four dishes to a density of about 5×105 cells/φ 10 cm dish were subcultured in 20 dishes to until the same density as the above, then again subcultured in 40 dishes (φ 15 cm) up to a density of about 5-6×106 cells / dish, and futher cultured in a differentiation medium (DMEM supplemented with 2% horse serum) for two days to finally form myotube. These cells were then scraped with a silicon rubber Policeman, washed two times with PBS, and suspended into the medium comprising 10% DMSO for storage at -80° C.

[0247] The #9-3 and #3-5 cells were suspended in physiological saline (200 μl), mixed with an equiamount of Freund's complete adjuvant (DIFCO) and intraperitoneally administered into Wistar rat (5 weeks old, female) in an amount of 1×107 cells/rat. The antigen was mixed with the same amount of Freund's incomplete adjuvant (DIFCO) and administered two weeks later in the same way as above.

[0248] (2) Evaluation of Antiserum

[0249] After one week from the boosting, the blood was drawn from the eyeground of the rat, and a binding of antiserum to Meltrin was determined by using the cell extract according to the plate assay of Example 10 (3). The cell extracts of #9-3, #3-5 and L929 cells were prepared according to the method of Example 10 (4), except that NP-40 (Nacarai Tesque Co.) was used at a final concentration of 0.5% as a surfactant.

[0250] First, each cell extract was dilulted with PBS to a concentration of 40 μg/ml, each 50 μl of which was separately poured into each well of an immuno plate (Maxisorp Nunc). After incubation at 56° C. for 30 min for binding of the antigen, the wells were washed five times with ion-exchanged water, blocked by 20% Block Ace (Yukijirushi Milk Co.)/PBS 100 μl, followed by incubation at a room temperature for 30 min. After removal of the blocking agent, each antiserum (50 μl) was added and incubated at 37° C. for one hour. After two repeats of washing of the wells with the washing liquid, 501 of an anti-rat immunoglobulins antibody labelled with peroxidase (Dako) and diluted 1,000 times with 10% Block Ace/PBS was added to each well followed by incubation at 37° C. for one hour. Upon the completion of the reaction, the wells were washed five times with the washing liquid and two times with ion-exchanged water, and 50 μl of 0.1 M McIlvaine buffer (pH 5.0) comprising 3 mg/ml of o-phenylene diamine and 0.027% hydro peroxide was added and reacted for 10 min. The reaction was terminated by the addition of 1N HCl (50 μl), and the absorbance at 490 nm was measured.

[0251] Western blotting was also carried out by using the cell extract of L4-3 described in the following (4) to confirm its binding to Meltrin. The results are shown in Table 6.

[0252] It was confirmed that the antiserum obtained from the rats immunized with #9-3 and #3-5 cells reacted with the corresponding cell extract, and were bound to Meltrin in the Western blotting.

6TABLE 6Reaction of antiserum of the rats immunized with #9-3 and#3-5 cells to MeltrinPlate AssayWestern blottingAntiserum#9-3#3-5L929L4-3rat immunized with+N.D.−+#9-3 cellrat immunized withN.D.+−+#3-5 cellN.D. (not determined)

[0253] (3) Preparation of Monoclonal Antibody

[0254] The #9-3 and #3-5 cells ( 1×107 cells each) were suspended in physiological saline (200 μl), and intraperitoneally administered into the rat whose antibody titer had increased. Three days later, cell fusion was carried out by using myeloma P3X63Ag8U.1 according to the known method (Monoclonal antibody Jikken Sosa Nyumon (Guide of monoclonal antibody preparation), Tamie Ando and Jo Chiba, Koudan-sha Scientific). Six days later, the culture supernatant was screened by its reactivity with the immobilized cell extracts. The wells that showed reactivity with the cell extracts were subjected to cloning by limiting dilution (Monoclonal antibody Jikken Sosa Nyumon (Guide of monoclonal antibody preparation), Tamie Ando and Jo Chiba, Koudan-sha Scientific). After cloning, the above screening was repeated to give 13 clones, 5 clone from the rat immunized with #9-3 (δPro; hybridoma No. F932) and 8 clones from the rat immunized with #3-5 (δMP; hybridoma No. F937).

[0255] (4) Evaluation of Monoconal Antibody

[0256] The monoclonal antibodies F932-15-2 (subclass IgGl) and F937-9-2 (subclass IgGl) that showed a high reactivity with the cell extracts were evaluated.

[0257] First, the staining of myotube formed by C2 cells was examined by a cell immunofluorescence staining method. C2 cells were suspended in 10% FCS/DMEM at a density of 3×104 cells/ml, each 100 μl of which was then separately poured into the wells of chamber slide (Lab-TEK, Nunc Co.). After the culture at 37° C. and 5% CO2 for two days, the medium was exchanged with 2% horse serum/DMEM. The cell staining was carried out by using myotube formed two days later. The cells were washed two times with PBS−, and 4% formaldehyde was added followed by the reaction at a room temperature for 30 min to fix the cells. The cells were washed three times with PBS− and blocked with 20% Block Ace T-PBS. After removal of the blocking agent, antibodies diluted to 10 g/ml with 20% Block Ace/T-PBS was added and reacted at a room temperature for one hour. After three repeats of washing of the wells with PBS−, an anti-rat immunoglobulins antibody FITC (Dako) diluted 20 times with 10% rabbit serum/T-PBS was added to each well followed by incubation a room temperature for one hour. After the completion of the incubation, the cells were washed three times with PBS−, and subjected to fluorescence microscopy. It was observed that myotube was stained by both the antibodies, but not stained by rat IgG (ZYMED) used as a negative control.

[0258] Next, L929 cells experssing mouse Meltrin α or β were prepared and subjected to cell staining for the purpose of confirmation of the specificity of the above antibodies. Thus, fibroblast L929 was transfected with the mixture comprising the plasmids pBOSMelα(+) and pBOSMelβ(+) prepared in Example 4, and the plasmid pSV2NEO in a molar ratio of 12:12:1 by using LIPOFECTAMINE (Gibco BRL) according to its protocol to give L4-3 cells expressing mouse Meltrins α and β. Similarly, L929 was transfected with the mixture comprising the plasmids pBOSMelβ(+) and the plasmid pSV2NEO in a molar ratio of 20:1 to give L2-10 cells expressing mouse Meltrin β. Similarly, L929 was transfected with the plasmids pBOSMelαδPro(+) to give L8-5 cells expressing mouse Meltrin α δPro. The transfected cells were cultured in 10% FCS/DMEM and subcultured onto a chamber slide. The specificity of the antibodies was confirmed by cell staining using L929, L4-3, L2-10 and L8-5 cells. The results shown in Table 7 indicated that F932-15-2 was bound to Meltrins α and β, and F937-9-2 was bound to Meltrin α.

[0259] The hybridoma expressing the monoclonal antibody F932-15-2 was deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken 350 Japan) on Oct. 3, 1996 under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and Regulation under accession numbers FERM BP-5687.

7TABLE 7CellExpressionF932-15-2F937-9-2L929−−−L4-3α and β++L2-10β+−L8-5α (δPro)++

[0260] (5) Determination of Neutralizing Activity

[0261] The neutralizing activity of the monoclonal antibodies obtained in the above (3) was confirmed by their inhibition of the formation of myotube by C2 cells. C2 cells were cultured in a collagen-coated dish contianing 10% FCS/DMEM till 80% of confluence, followed by exchange of the medium with 2% horse serum/DMEM supplemented with 0 or 4 μg/ml of the antibodies to be tested. The formation of byotube was then observed and the ratio of nuclei in the formed myotube was calculated. As seen from FIG. 20, the formation of myotube on the day 2 was inhibited, showing that both F932-15-2 and F937-9-2 have the neutralizing activity.

Example 12

[0262] The Activity of Meltrin neutralizing Antibodies to Inhibit the Formation of Bone Resorption Area (Pit) in Mouse Unfractionated Bone Cells

[0263] Femur and tibia extracted from 13-day-old ICR mouse were crushed in MEM a medium (GIBCO) supplemented with 5% FBS. After being allowed to stand still for 2 min, the precipitaed bone residues were removed. The supernatant of the suspending cells was adjusted to 1×107 cells/ml, 100 μl of which was then added to each well of a 96 well microplate provided with ivory fragments. The ivory fragments had been thinly sliced, punched into 6 mm in diameter, washed with 70% ethanol and sterilized. The mouse Meltrin-neutralizing antibody (F932-15-2) obtained in Example 11, and rat IgG were diluted with MEM a medium (GIBCO) supplemented with 5% FBS to final concentrations of 5, 50, and 500 μg/ml, 100 μl of which was then added to each well. After incubation at 37° C. and 5% CO2 for three days, the cells were removed with a scraper, and resorption area was stained with an acid hematoxylin solution (SIGMA) for about 7 min and the number of the stained resorption area was caluculated using an ocular micrometer under a microscope by counting the number of squares wherein resorption fossa was contained.

[0264] The results are shown in FIG. 21, which demonstrates that the number of the formed resorption area was inhibited in a dose-depending manner by the mouse Meltrin-neutralizing antibody. Accordingly, it was suggested that the Meltrin-neutralizing antibody would affect directly or indirectly osteoclast and inhibit bone resorption.

Example 13

[0265] Serum Ca-decreasing Activity of Meltrin-Neutralizing Antibody in Mouse Having Enhanced Bone Resorption

[0266] Seven-week-old ICR mice (male) were fed for five days with low Ca feed with Ca content of 0.02% or less. The mouse Meltrin-neutralizing antibody (F932-15-2) obtained in Example 11 was injected into the tail vein of the mice (one group consisting of five mice) at doses of 0.1 mg and 1 mg per mouse). Rat IgG (1 mg per mouse) and phosphate buffer physiological saline were also injected as a control in the same way. Before injection and one day later, the blood was collected from the vein under eyes, and serum was separated. The value of Ca in the serum was then determined by an autoanalyzer (COBAS FARAII, ROCHE) using Ca determination kit (CalciumHR-II, WAKO Pure Pharmaceuticals). The results are shown in FIG. 22.

[0267] As seen from FIG. 22, the serum Ca value after one day from the injection in the groups treated with the mouse Meltrin-neutralizing antibody was lower than that of the groups treated with rat IgG or physiological saline. These results suggested that the Meltrin-neutralizing antibody would inhibit an unhealthly enhanced bone resorption due to hyperparathyroidism or malignant hypercalcemia.

Example 14

[0268] Preparation of cDNA Fragment Encoding Human Meltrin α Comprising Transmembrane Domain

[0269] A sense primer S-hMelα-TM5′ was synthesized based on the partial cDNA sequence of human Meltrin α obtained in Example 8, and an antisense primer A-mMelα-3′ was synthersized based on the cDNA sequence of mouse Meltrin α (see Table 1).

[0270] PCR was carried out by mixing the human placenta λgt11 cDNA library (Clonetech Co., code No. CLHL1008b) as a template, with S-hMelα-TM5′and A-mMelα-3′ primers, Ex Taq polymerase (TaKaRa Co.,), and its reagents (TaKaRa Co.,), followed by 35 cycles of the reactions at 94° C. for 30 sec, 55° C. for 30 sec, and 72° C. for one min. The base sequencing of the resulting amplified fragment (clone TM) suggested that the fragment was a human cDNA fragment corresponding to about 220 amino acids comprising the transmembrane domain of mouse Meltrin.

[0271] The obtained base sequence and its corresponding amino acid sequence are shown in FIG. 23a˜FIG. 23b.

[0272] The mouse Meltrin-neutralizing antibody (F932-15-2) obtained in Example 11 was injected into seven-week-old ICR male mice (one group consisting of five mice) at doses of 1 mg and 3 mg per mouse). Phosphate buffer physiological saline was also injected into a control group in the same way. Neither significant decrease of body weight nor side effect was observed in any group after the injection. No dead mouse was observed, either.

reference Example 1

[0273] Preparation of Monoclonal Antibody Recognizing Human Meltrin

[0274] (1) Preparation of Antibody Using a Peptide Having the Amino Acid Sequence Derived from Human Meltrin as an Antigen

[0275] In consideration of the results obtained in Example 10, the sequence “GKVSKSSFAKCEMRDAKC” corresponding to DC-C in the amino acid sequence of human Meltrin α obtained in Example 8 was synthesized in the same way as in Example 10 (1), purified and conjugated with maleimidated KLH to give an antigen to be administered. 20 μg of the antigen was dissolved in 0.1 ml of physiological saline and mixed with an equiamount of FCA followed by injection to ddy mouse (5 weeks old, female). The same amount of the antigen was mixed with FIA and injected two weeks later. The blood was collected from the eyeground one week later and antiserum was prepared. Evaluation of the reactivity of the resulting antiserum with the administered peptide according to the method of Example 10 (3) revealed its specific reactivity with the administered peptide. Accordingly, mouse, rat, hamster and the like are immunized with the peptide antigen, and monoclonal antibody may be prepared in the same manner as in Example 10 (5). Such antibody may also be used in Western blotting.

[0276] As it is estimated that the amino acid sequence in FIG. 15a˜FIG. 15fis Meltrin α of a soluble type, an antibody, which may be effectively used in the determination of soluble Meltrin in the body, may be prepared by immunization of a peptide having the amino acid sequence adjacent to C-termial of the above sequence.

[0277] Similarly, antibodies recognizing human Meltrin β and Meltrin γ may be prepared by chemically synthesizing peptides having the amino acid sequences of suitable parts in the amino acid sequences in FIG. 17a˜FIG. 17cor FIG. 13a˜FIG. 13d and injecting the thus synthesized peptides into animals. In any case, the amino acid sequence will be selected from the extracellular domain.

[0278] For the preparation of an antibody specific to each one of Meltrins α, β and γ, the amino acid sequence should be selected from the parts with a low homology among them, and a peptide having the thus selected amino acid sequence is synthesized and injected to animals such as mouse, rat and hamster in the same way as in Example 10 (2).

[0279] In any case, monoclonal antibodies are prepared in the same way as in Example 10 (5).

[0280] (2) Preparation of Anti-Meltrin Monoclonal Antibody Using Cells Expressing Human Meltrin as an Antigen

[0281] DNA encoding the amino acid sequence wherein the amino acid sequence located downstream of the transmembrane domain shown in FIG. 23a˜FIG. 23b is fused downstream of the sequence from the metalloproteinase or the disintegrin domain to the cysteine-rich region shown in FIG. 15a˜FIG. 15f is prepared, and inserted into an expression vector pEFBOS, followed by transformation of C2 cells by the resulting vector. The transformant is treated as in Example 11 (1), and used as an antigen for immunization of animals such as mouse, rat and hamster. Antibodies recognizing human Meltrin α is screened as in Example 11 (2), and monoclonal antibodies are prepared as in Example 11 (3).

[0282] Similarly, DNA encoding the amino acid sequence shown in FIG. 17a˜FIG. 17c or the sequence located downstream of the disintegrin domain of the above sequence is prepared, and inserted into an expression vector pEFBOS, followed by transformation of C2 cells by the resulting vector. The transformant is treated as in Example 11 (1), and used as an antigen for immunization of animals such as mouse, rat and hamster. Antibodies recognizing human Meltrin β is screened as in Example 11 (2), and monoclonal antibodies are prepared as in Example 11 (3).

[0283] Similarly, DNA encoding the amino acid sequence shown in FIG. 13a˜FIG. 13d or the sequence located downstream of the disintegrin domain of the above sequence is prepared, and inserted into an expression vector pEFBOS, followed by transformation of C2 cells by the resulting vector. The transformant is treated as in Example 11 (1), and used as an antigen for immunization of animals such as mouse, rat and hamster. Antibodies recognizing human Meltrin γ is screened as in Example 11 (2), and monoclonal antibodies are prepared as in Example 11 (3).

Claims

1. Meltrin which is a protein involved in fusion, adhesion or aggregation of cells.
2. Meltrin of claim 1, which is a mouse Meltrin.
3. Meltrin of claim 1, which is a human Meltrin.
4. Meltrin of claim 1 or 2, which is any one of Meltrin α, β and γ comprising the amino acid sequence shown in FIG. 2a˜FIG. 2j, FIG. 3a˜FIG. 3j and FIG. 4a˜FIG. 4i, respectively.
5. Meltrin of claim 1 or 3, which is any one of Meltrin α, β and γ comprising the amino acid sequence shown in FIG. 12a˜FIG. 12b, FIG. 15a˜FIG. 15f or FIG. 23a˜FIG. 23b; FIG. 16 or FIG. 17a˜FIG. 17c; and FIG. 13a˜FIG. 13d, respectively.
6. A polypeptide comprising at least a part of the protein, Meltrin, involved in fusion, adhesion or aggregation of cells.
7. A polypeptide of claim 6, comprising at least a metalloproteinase domain, disintegrin domain, and cysteine-rich region of Meltrin.
8. A polypeptide of claim 6, comprising at least a disintegrin domain, and cysteine-rich region of Meltrin.
9. A polypeptide of claim 6, selected from the group consisting of an intracellular domain, transmembrane domain, precursor domain, metalloproteinase domain, disintegrin domain, fusion peptide-like sequence, and cysteine-rich region of Meltrin; and the combination of any of the above domains in any order.
10. A polypeptide of claim 6, comprising a part of the amino acid sequences of a metalloproteinase domain and disintegrin domain of Meltrin.
11. A polypeptide of claim 6, comprising at least a part of the amino acid sequences shown in FIG. 2a˜FIG. 2j, FIG. 3a˜FIG. 3j, FIG. 4a˜FIG. 4i, FIG. 12a˜FIG. 12b, FIG. 15a˜FIG. 15f, FIG. 23a˜FIG. 23b, FIG. 16, FIG. 17a˜FIG. 17c or FIG. 13a˜FIG. 13d.
12. A polypeptide of any one of claims 7 to 10, wherein each domain essentially contains any one of the following amino acid sequences: Precursor domain: 1) amino acid sequence of Met (No.1) to Arg (No.205) from N-terminal in FIG. 2a˜FIG. 2j, 2) amino acid sequence of Met (No.1) to Arg (No.204) from N-terminal in FIG. 3a˜FIG. 3j, 3) amino acid sequence of Met (No.1) to Arg (No.205) from N-terminal in FIG. 4a˜FIG. 4i, and 4) amino acid sequence of Gly (No.1) to Arg (No.155) from N-terminal in FIG. 15a˜FIG. 15f; metalloproteinase domain: 1) amino acid sequence of Glu (No.206) to Pro (No.414) from N-terminal in FIG. 2a˜FIG. 2j, 2) amino acid sequence of Glu (No.205) to Pro (No.409) from N-terminal in FIG. 3a˜FIG. 3j, 3) amino acid sequence of Ala (No.206) to Pro (No.406) from N-terminal in FIG. 4a˜FIG. 4i, 4) amino acid sequence of Glu (No.156) to Pro (No.364) from N-terminal in FIG. 15a˜FIG. 15f, 5) amino acid sequence of Gly (No.1) to Pro (No.36) from N-terminal in FIG. 17a˜FIG. 17c, and 6) amino acid sequence of Ala (No.1) to Pro (No.40) from N-terminal in FIG. 13a˜FIG. 13d; Disintegrin domain: 1) amino acid sequence of Phe (No.420) to Gly (No.509) from N-terminal in FIG. 2a˜FIG. 2j, 2) amino acid sequence of Tyr (No.415) to Gly (NO.504) from N-terminal in FIG. 3a˜FIG. 3j, 3) amino acid sequence of Tyr (No.412) to Gly (No.502) from N-terminal in FIG. 4a˜FIG. 4i, 4) amino acid sequence of Lys (No.1) to Gly (No.36) from N-terminal in FIG. 12a˜FIG. 12b, 5) amino acid sequence of Phe (No.370) to Gly (No.459) from N-terminal in FIG. 15a˜FIG. 15f, 6) amino acid sequence of Gly (No.1) to Gly (No.77) from N-terminal in FIG. 16, 7) amino acid sequence of Tyr (No.42) to Gly (No.131) from N-terminal in FIG. 17a˜FIG. 17c, and 8) amino acid sequence of Tyr (No.46) to Gly (No.136) from N-terminal in FIG. 13a˜FIG. 13d; cysteine-rich region: 1) amino acid sequence of His (No.510) to Gly (No.706) from N-terminal in FIG. 2a˜FIG. 2j, 2) amino acid sequence of Thr (No.505) to Pro (No.706) from N-terminal in FIG. 3a˜FIG. 3j, 3) amino acid sequence of Tyr (No.503) to Ala (No.694) from N-terminal in FIG. 4a˜FIG. 4i, 4) amino acid sequence of His (No.37) to Lys (No.107) from N-terminal in FIG. 12a˜FIG. 12b, 5) amino acid sequence of His (No.460) to Gln (No.656) from N-terminal in FIG. 15a˜FIG. 15f, 6) amino acid sequence of Thr (No.78) to Arg (No.131) from N-terminal in FIG. 16, 7) amino acid sequence of Thr (No.132) to Pro (No.330) from N-terminal in FIG. 17a˜FIG. 17c, and 8) amino acid sequence of Tyr (No.137) to Ser (No.322) from N-terminal in FIG. 13a˜FIG. 13d; Fusion peptide-like sequence: 1) amino acid sequence of Gly (No.585) to Glu (No.607) from N-terminal in FIG. 2a˜FIG. 2j, and 2) amino acid sequence of Gly (No.535) to Gln (No.557) from N-terminal in FIG. 15a˜FIG. 15f; Transmembrane domain: 1) amino acid sequence of Leu (No.707) to Leu (No.727) from N-terminal in FIG. 2a˜FIG. 2j, 2) amino acid sequence of Val (No.707) to Arg (No.729) from N-terminal in FIG. 3a˜FIG. 3j, 3) amino acid sequence of Leu (No.695) to Ile (No.714) from N-terminal in FIG. 4a˜FIG. 4i, 4) amino acid sequence of Leu (No.74) to Leu (No.94) from N-terminal in FIG. 23a˜FIG. 23b, and 5) amino acid sequence of Val (No.331) to Met (No.348) from N-terminal in FIG. 17a˜FIG. 17c; and Intracellular domain: 1) amino acid sequence of Lys (No.728) to Lys (No.903) from N-terminal in FIG. 2a˜FIG. 2j, 2) amino acid sequence of Gln (No.730) to Ile (No.920) from N-terminal in FIG. 3a˜FIG. 3j, 3) amino acid sequence of Phe (No.715) to Thr (No.845) from N-terminal in FIG. 4a˜FIG. 4i, 4) amino acid sequence of Lys (No.95) to Leu (No.207) from N-terminal in FIG. 23a˜FIG. 23b, and 5) amino acid sequence of Tyr (No.349) to Lys (No.394) from N-terminal in FIG. 17a˜FIG. 17c.
13. A DNA comprising the base sequence encoding Meltrin of any one of claims 1 to 3.
14. A DNA comprising the base sequence encoding Meltrin of claim 4.
15. A DNA comprising the base sequence encoding Meltrin of claim 5.
16. A DNA of claim 14, comprising any one of the following base sequences: 1) base No. 221˜2929 in FIG. 5a˜FIG. 5j, 2) base No. 63˜2822 in FIG. 6a˜FIG. 6h, and 3) base No. 69˜2603 in FIG. 7a˜FIG. 7e.
17. A DNA of claim 15, comprising any one of the following base sequences: 1) base No. 1˜321 in FIG. 12a˜FIG. 12b, 2) base No. 1˜2058 in FIG. 15a˜FIG. 15f, 3) base No. 3˜623 in FIG. 23a˜FIG. 23b, 4) base No. 1˜393 in FIG. 16, 5) base No. 2˜1183 in FIG. 17a˜FIG. 17c, and 6) base No. 1˜966 in FIG. 13a˜FIG. 13d.
18. A DNA comprising the base sequence encoding the polypeptide of claim 6.
19. A DNA comprising the base sequence encoding any one of the polypeptides of claims 7 to 10 and 12.
20. A DNA of claim 18, which is a part of any one of the base sequences shown in FIG. 5a˜FIG. 5j, FIG. 6a˜FIG. 6h, FIG. 7a˜FIG. 7e, FIG. 12a˜FIG. 12b, FIG. 15a˜FIG. 15f, FIG. 23a˜FIG. 23b, FIG. 16, FIG. 17a˜FIG. 17c, and FIG. 13a˜FIG. 13d.
21. A DNA of claim 19, essentially comprising any one of the following base sequences or the combination thereof in any order: (1) base No. 221˜835 in FIG. 5a˜FIG. 5j, (2) base No. 836˜1462 in FIG. 5a˜FIG. 5j, (3) base No. 1478˜1747 in FIG. 5a˜FIG. 5j, (4) base No. 1748˜2338 in FIG. 5a˜FIG. 5j, (5) base No. 2339˜2401 in FIG. 5a˜FIG. 5j, (6) base No. 1973˜2041 in FIG. 5a˜FIG. 5j, (7) base No. 2402˜2929 in FIG. 5a˜FIG. 5j, (8) base No. 63˜674 in FIG. 6a˜FIG. 6h, (9) base No. 675˜1289 in FIG. 6a˜FIG. 6h, (10) base No. 1305˜1574 in FIG. 6a˜FIG. 6h, (11) base No. 1575˜2180 in FIG. 6a˜FIG. 6h, (12) base No. 2181˜2249 in FIG. 6a˜FIG. 6h, (13) base No. 2250˜2822 in FIG. 6a˜FIG. 6h, (14) base No. 69˜683 in FIG. 7a˜FIG. 7c, (15) base No. 684˜1292 in FIG. 7a˜FIG. 7c, (16) base No. 1302˜1574 in FIG. 7a˜FIG. 7c, (17) base No. 1575˜2150 in FIG. 7a˜FIG. 7c, (18) base No. 2151˜2210 in FIG. 7a˜FIG. 7c, (19) base No. 2211˜2603 in FIG. 7a˜FIG. 7c, (20) base No. 1˜108 in FIG. 12a˜FIG. 12b, (21) base No. 109˜321 in FIG. 12a˜FIG. 12b, (22) base No. 1˜465 in FIG. 15a˜FIG. 15f, (23) base No. 466˜1092 in FIG. 15a˜FIG. 15f, (24) base No. 1108˜1377 in FIG. 15a˜FIG. 15f, (25) base No. 1378˜1968 in FIG. 15a˜FIG. 15f, (26) base No. 3˜221 in FIG. 23a˜FIG. 23b, (27) base No. 222˜284 in FIG. 23a˜FIG. 23b, (28) base No. 285˜623 in FIG. 23a˜FIG. 23b, (29) base No. 1˜231 in FIG. 16, (30) base No. 232˜393 in FIG. 16, (31) base No. 2˜109 in FIG. 17a˜FIG. 17c, (32) base No. 125˜394 in FIG. 17a˜FIG. 17c, (33) base No. 395˜991 in FIG. 17a˜FIG. 17c, (34) base No. 992˜1045 in FIG. 17a˜FIG. 17c, (35) base No. 1046˜1183 in FIG. 17a˜FIG. 17c, (36) base No. 1˜120 in FIG. 13a˜FIG. 13d, (37) base No. 136˜408 in FIG. 13a˜FIG. 13d, (38) base No. 409˜966 in FIG. 13a˜FIG. 13d, and (39) base No. 1603˜1671 in FIG. 15a˜FIG. 15f.
22. An antisense oligonucleotide or its derivative for any one of DNAs of claims 13 to 21.
23. An antiody recognizing Meltrin of claim 1, 2, 3, 4 or 5, or the polypeptide of claim 6, 7, 8, 9, 10, 11 or 12.
24. An antibody obtainable by using Meltrin or a part thereof of claim 1, 2, 3, 4 or 5 as an antigen.
25. An antibody obtainable by using the polypeptide or a fragment thereof of claim 6, 7, 8, 9, 10, 11 or 12 as an antigen.
26. An antibody of claim 23, 24 or 25, which is a neutralizing antibody.
27. An antibody of claim 23, 24, 25 or 26, which is a monoclonal antibody.
28. A vector comprising at least any one of the DNAs of claims 13 to 17.
29. A vector comprising at least any one of the DNAS of claims 18 to 21.
30. A transformant by the vector of claim 28.
31. A transformant by the vector of claim 29.
32. A transformant of claim 30, which is a eukaryotic cell.
33. A transformant of claim 30, which is E.coli.
34. A transformant of claim 31, which is a eukaryotic cell.
35. A transformant of claim 31, which is E.coli.
36. A process for producing Meltrin of claim 1, 2, 3, 4 or 5, comprising culturing the transformant of claim 30, 32 or 33.
37. A process for producing the polypeptide of claim 6, 7, 8, 9, 10, 11 or 12, comprising culturing the transformant of claim 31, 34 or 35.
38. Meltrin comprising an amino acid sequence encoded by the base sequence hybridizing the base sequence complementary to the base sequence encoding Meltrin of claim 4 or 5.
39. A polypeptide comprising an amino acid sequence encoded by the base sequence hybridizing the base sequence complementary to the base sequence encoding the polypeptide of claim 12.
40. A DNA comprising a base sequence encoding Meltrin of claim 1, which hybridizes the base sequence complementary to any one of the following base sequences: 1) base No. 221˜2929 in FIG. 5a˜FIG. 5j, 2) base No. 1478˜1747 in FIG. 5a˜FIG. 5j, 3) base No. 63˜2822 in FIG. 6a˜FIG. 6h, 4) base No. 1305˜1574 in FIG. 6a˜FIG. 6h, 5) base No. 69˜2603 in FIG. 7a˜FIG. 7e, 6) base No. 1302˜1574 in FIG. 7a˜FIG. 7e, 7) base No. 1˜321 in FIG. 12a˜FIG. 12b, 8) base No. 1˜2058 in FIG. 15a˜FIG. 15f, 9) base No. 1108˜1377 in FIG. 15a˜FIG. 15f, 10) base No. 3˜623 in FIG. 23a˜FIG. 23b, 11) base No. 1˜393 in FIG. 16, 12) base No. 2˜1183 in FIG. 17a˜FIG. 17c, 13) base No. 125˜394 in FIG. 17a˜FIG. 17c, 14) base No. 1˜966 in FIG. 13a˜FIG. 13d, and 15) base No. 136˜408 in FIG. 13a˜FIG. 13d.
41. A DNA having a base sequence encoding the polypeptide of claim 6, which hybridizes the base sequence complementary to a part of any one of the following base sequences: (1) base No. 221˜835 in FIG. 5a˜FIG. 5j, (2) base No. 836 1462 in FIG. 5a˜FIG. 5j, (3) base No. 1478˜1747 in FIG. 5a˜FIG. 5j, (4) base No. 1748˜2338 in FIG. 5a˜FIG. 5j, (5) base No. 2339˜2401 in FIG. 5a˜FIG. 5j, (6) base No. 1973˜2041 in FIG. 5a˜FIG. 5j, (7) base No. 2402˜2929 in FIG. 5a˜FIG. 5j, (8) base No. 63˜674 in FIG. 6a˜FIG. 6h, (9) base No. 675˜1289 in FIG. 6a˜FIG. 6h, (10) base No. 1305˜1574 in FIG. 6a˜FIG. 6h, (11) base No. 1575˜2180 in FIG. 6a˜FIG. 6h, (12) base No. 2181˜2249 in FIG. 6a˜FIG. 6h, (13) base No. 2250˜2822 in FIG. 6a˜FIG. 6h, (14) base No. 69˜683 in FIG. 7a˜FIG. 7e, (15) base No. 684˜1292 in FIG. 7a˜FIG. 7e, (16) base No. 1302˜1574 in FIG. 7a˜FIG. 7e, (17) base No. 1575˜2150 in FIG. 7a˜FIG. 7e, (18) base No. 2151˜2210 in FIG. 7a˜FIG. 7e, (19) base No. 2211˜2603 in FIG. 7a˜FIG. 7e, (20) base No. 1˜108 in FIG. 12a˜FIG. 12b, (21) base No. 109˜321 in FIG. 12a˜FIG. 12b, (22) base No. 1˜465 in FIG. 15a˜FIG. 15f, (23) base No. 466˜1092 in FIG. 15a˜FIG. 15f, (24) base No. 1108˜1377 in FIG. 15a˜FIG. 15f, (25) base No. 1378˜1968 in FIG. 15a˜FIG. 15f, (26) base No. 3˜221 in FIG. 23a˜FIG. 23b, (27) base No. 222˜284 in FIG. 23a˜FIG. 23b, (28) base No. 285˜623 in FIG. 23a˜FIG. 23b, (29) base No. 1˜231 in FIG. 16, (30) base No. 232˜393 in FIG. 16, (31) base No. 2˜109 in FIG. 17a˜FIG. 17c, (32) base No. 125˜394 in FIG. 17a˜FIG. 17c, (33) base No. 395˜991 in FIG. 17a˜FIG. 17c, (34) base No. 992˜1045 in FIG. 17a˜FIG. 17c, (35) base No. 1046˜1183 in FIG. 17a˜FIG. 17c, (36) base No. 1˜120 in FIG. 13a˜FIG. 13d, (37) base No. 136˜408 in FIG. 13a˜FIG. 13d, (38) base No. 409˜966 in FIG. 13a˜FIG. 13d, and (39) base No. 1603˜1671 in FIG. 15a˜FIG. 15f.
42. A medical composition comprising Meltrin of claim 1 or the polypeptide of claim 6 as an effective ingredient.
43. A medical composition comprising an antagonist against Meltrin as an effective ingredient.
44. A medical composition of claim 43, wherein the antagonist is the polypeptide of any one of claims 6 to 12.
45. A medical composition of claim 43, wherein the antagonist is the antisense oligonucleotide or its derivative of claim 22.
46. A medical composition of claim 45, wherein the antagonist is the antibody of claim 26 or 27.
47. A medical composition of any one of claims 42 to 46, having the activity of inhibiting bone resorption.
48. A medical composition of claim 47, which is a treating agent for osteoporosis or hypercalcemia.
49. An isolated Meltrin.
50. An isolated Meltrin of claim 49, being human Meltrin.
51. An isolated Meltrin of claim 49, being mouse Meltrin.
52. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of the sequence of Seq. ID No. 2, Seq. ID No. 4, and Seq. ID No. 6.
53. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of Seq. ID Nos. 8, 12, 18, 14, 16, and 10.
54. An isolated polypeptide comprising at least a part of an amino acid sequence of Meltrin, and having cell fusion, cell adhesion, or cell aggregation activity.
55. An isolated polypeptide according to claim 54, having an amino acid sequence selected from the group consisting of at least one of the following sequences of Meltrin: an intracellular domain, a transmembrane domain, a precursor domain, a metalloproteinase domain, a disintegrin domain, a fusion peptide-like sequence, and a cystein-rich region of Meltrin.
56. An isolated polypeptide according to claim 54 comprising at least the following sequences of Meltrin: a mealloproteinase domain, and a disintegrin domain.
57. An isolated polypeptide sequence according to claim 54, comprising at least a part of an amino acid sequence selected from the group consisting of: the sequence of Seq. ID No. 2, the sequence of Seq. ID No. 4, the sequence of Seq. ID No. 6, the sequence of Seq. ID No. 8, the sequence of Seq. ID No. 12, the sequence of Seq. ID No. 18, the sequence of Seq. ID No. 14, the sequence of Seq. ID No. 16, and the sequence of Seq. ID No. 10.
58. An isolated polypeptide according to claim 55, wherein the precursor domain is selected from the group consisting of (1) an amino acid sequence of Met (No. 1) to Arg (No. 205) from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Met (No. 1) to Arg (No. 204) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Met (No. 1) to Arg (No. 205) from an N-terminal in Seq. ID No. 6, and (4) an amino acid sequence of Gly (No. 1) to Arg (No. 155) from an N-terminal in Seq. ID No. 12; wherein said metalloproteinase domain is selected from the group consisting of (1) an amino acid sequence of Glu (No. 206) to Pro (No. 414) from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Glu (No. 205) to Pro (No. 409) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Ala (No. 206) to Pro (No. 406) from an N-terminal in Seq. ID No. 6, (4) an amino acid sequence of Glu (No. 156) to Pro (No. 364) from an N-terminal in Seq. ID No. 12, (5) an amino acid sequence of Gly (No. 1) to Pro (No. 36) from an N-terminal in Seq. ID No. 16, and (6) an amino acid sequence of Ala (No. 1) to Pro (No. 40) from N-terminal in Seq. ID No. 10; wherein said disintegrin domain is selected from the group consisting of (1) an amino acid sequence of Phe (No. 420) to Gly (No. 509) from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Tyr (No. 415) to Gly (No. 504) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Tyr (No. 412) to Gly (No. 502) from an N-terminal in Seq. ID No. 6, (4) an amino acid sequence of Lys (No. 1) to Gly (No. 36) from an N-terminal in Seq. ID No. 8, (5) an amino acid sequence of Phe (No. 370) to Gly (No. 459) from an N-terminal in Seq. ID No. 12, (6) an amino acid sequence of Gly (No. 1) to Gly (No. 77) from an N-terminal in Seq. ID No. 14, (7) an amino acid sequence of Tyr (No. 42) to Gly (No. 131) from an N-terminal in Seq. ID No. 16, and (8) an amino acid sequence of Tyr (No. 46) to Gly (No. 136) from an N-terminal in Seq. ID No. 10; wherein said cystein rich region is selected from the group consisting of (1) an amino acid sequence of His (No. 510) to Gly (No. 706) from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Thr (No. 505) to Pro (No. 706) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Tyr (No. 503) to Ala (No. 694) from an N-terminal in Seq. ID No. 6, (4) an amino acid sequence of His (No. 37) to Lys (No. 107) from an N-terminal in Seq. ID No. 8, (5) an amino acid sequence of His (No. 460) to Gln (No. 656) from an N-terminal in Seq. ID No. 12, (6) an amino acid sequence of Thr (No. 78) to Arg. (No. 131) from an N-terminal in Seq. ID No. 14, (7) an amino acid sequence of Thr (No. 132) to Pro (No. 330) from an N-terminal in Seq. ID No. 16, and (8) an amino acid sequence of Tyr (No. 137) to Ser. (No. 322) from an N-terminal in Seq. ID No. 10; wherein said fusion peptide-like sequence is selected from the group consisting of (1) an amino acid sequence of Gly (No. 585) to Glu (No. 607)from an N-terminal in Seq. ID No. 2, and (2) an amino acid sequence of Gly (No. 535) to Gln (No. 557) from an N-terminal in Seq. ID No. 12; wherein said transmembrane domain is selected from the group consisting of (1) an amino acid sequence of Leu (No. 707) to Leu (No. 727)from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Val (No. 707) to Arg (No. 729) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Leu (No. 695) to Ile (No. 714) from an N-terminal in Seq. ID No. 6, (4) an amino acid sequence of Leu (No. 74) to Leu (No. 94) from an N-terminal in Seq. ID No. 18, (5) an amino acid sequence of Val (No. 331) to Met (No. 348) from an N-terminal in Seq. ID No. 16; and wherein said intracellular domain is selected from the group consisting of (1) an amino acid sequence of Lys (No. 728) to Lys (No. 903)from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Gln (No. 730) to Ile (No. 920) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Phe (No. 715) to Thr (No. 845) from an N-terminal in Seq. ID No. 6, (4) an amino acid sequence of Lys (No. 95) to Leu (No. 207) from an N-terminal in Seq. ID No. 18, and (5) an amino acid sequence of Tyr (No. 349) to Lys (No. 394) from an N-terminal in Seq. ID No. 16.
59. An isolated DNA encoding the polypeptide comprising an amino acid sequence selected from the group consisting of the sequence of Seq. ID Nos. 2, 4 and 6.
60. An isolated DNA encoding the polypeptide comprising an amino acid sequence selected from the group consisting of the sequence of Seq. ID Nos. 8, 12, 18 and 10.
61. An isolated DNA according to claim 59, comprising a sequence selected from the group consisting of: (1) base No. 221˜2929 in Seq. ID No. 1, (2) bases Nos. 63˜2822 in Seq. ID No. 3, and (3) bases Nos. 69˜2603 in Seq. ID No. 5.
62. An isolated DNA according to claim 60, comprising a base sequence selected from the group consisting of: (1) bases Nos. 1˜321 in Seq. ID No. 7, (2) bases Nos. 1˜2058 in Seq. ID No. 11, (3) bases Nos. 3˜623 in Seq. ID No. 17, and (4) bases Nos. 1˜966 in Seq. ID No. 9.
63. An isolated DNA encoding the polypeptide having at least one of the following part of mertlin: a precursor domain, a metalloproteinase domain, a disintegrin domain, a fusion peptide-like sequence, and a crystein-rich region, wherein the precursor domain is selected from the group consisting of (1) an amino acid sequence of Met (No. 1) to Arg (No. 205) from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Met (No. 1) to Arg (No. 204) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Met (No. 1) to Arg (No. 205) from an N-terminal in Seq. ID No. 6, and (4) an amino acid sequence of Gly (No. 1) to Arg (No. 155) from an N-terminal in Seq. ID No. 12; wherein said metalloproteinase domain is selected from the group consisting of (1) an amino acid sequence of Glu (No. 206) to Pro (No. 414) from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Glu (No. 205) to Pro (No. 409) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Ala (No. 206) to Pro (No. 406) from an N-terminal in Seq. ID No. 6, (4) an amino acid sequence of Glu (No. 156) to Pro (No. 364) from an N-terminal in Seq. ID No. 12, and (5) an amino acid sequence of Ala (No. 1) to Pro (No. 40) from N-terminal in Seq. ID No. 10; wherein said disintegrin domain is selected from the group consisting of (1) an amino acid sequence of Phe (No. 420) to Gly (No. 509) from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Tyr (No. 415) to Gly (No. 504) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Tyr (No. 412) to Gly (No. 502) from an N-terminal in Seq. ID No. 6, (4) an amino acid sequence of Lys (No. 1) to Gly (No. 36) from an N-terminal in Seq. ID No. 8, (5) an amino acid sequence of Phe (No. 370) to Gly (No. 459) from an N-terminal in Seq. ID No. 12, and (6) an amino acid sequence of Tyr (No. 46) to Gly (No. 136) from an N-terminal in Seq. ID No. 10; wherein said cystein rich region is selected from the group consisting of (1) an amino acid sequence of His (No. 510) to Gly (No. 706) from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Thr (No. 505) to Pro (No. 706) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Tyr (No. 503) to Ala (No. 694) from an N-terminal in Seq. ID No. 6, (4) an amino acid sequence of His (No. 37) to Lys (No. 107) from an N-terminal in Seq. ID No. 8, (5) an amino acid sequence of His (No. 460) to Gln (No. 656) from an N-terminal in Seq. ID No. 12, and (6) an amino acid sequence of Tyr (No. 137) to Ser. (No. 322) from an N-terminal in Seq. ID No. 10; wherein said fusion peptide-like sequence is selected from the group consisting of (1) an amino acid sequence of Gly (No. 585) to Glu (No. 607)from an N-terminal in Seq. ID No. 2, and (2) an amino acid sequence of Gly (No. 535) to Gln (No. 557) from an N-terminal in Seq. ID No. 12; wherein said transmembrane domain is selected from the group consisting of (1) an amino acid sequence of Leu (No. 707) to Leu (No. 727)from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Val (No. 707) to Arg (No. 729) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Leu (No. 695) to Ile (No. 714) from an N-terminal in Seq. ID No. 6, and (4) an amino acid sequence of Leu (No. 74) to Leu (No. 94) from an N-terminal in Seq. ID No. 18, and wherein said intracellular domain is selected from the group consisting of (1) an amino acid sequence of Lys (No. 728) to Lys (No. 903)from an N-terminal in Seq. ID No. 2, (2) an amino acid sequence of Gln (No. 730) to Ile (No. 920) from an N-terminal in Seq. ID No. 4, (3) an amino acid sequence of Phe (No. 715) to Thr (No. 845) from an N-terminal in Seq. ID No. 6, and (4) an amino acid sequence of Lys (No. 95) to Leu (No. 207) from an N-terminal in Seq. ID No. 18.
64. An isolated DNA comprising at least one of the base sequences selected from the group consisting of: (1) bases Nos. 221˜835 in Seq. ID No. 1, (2) bases Nos. 836˜1462 in Seq. ID No. 1, (3) bases Nos. 1478˜1747 in Seq. ID No. 1, (4) bases Nos. 1748˜2338 in Seq. ID No. 1, (5) bases Nos. 2339˜2401 in Seq. ID No. 1, (6) bases Nos. 1973˜2041 in Seq. ID No. 1, (7) bases Nos. 2402˜2929 in Seq. ID No. 1, (8) bases Nos. 63˜674 in Seq. ID No. 3, (9) bases Nos. 675˜1289 in Seq. ID No. 3, (10) bases Nos. 1305˜1574 in Seq. ID No. 3, (11) bases Nos. 1575˜2180 in Seq. ID No. 3, (12) bases Nos. 2181˜2249 in Seq. ID No. 3, (13) bases Nos. 2250˜2822 in Seq. ID No. 3, (14) bases Nos. 69˜683 in Seq. ID No. 5, (15) bases Nos. 684˜1292 in Seq. ID No. 5, (16) bases Nos. 1302˜1574 in Seq. ID No. 5, (17) bases Nos. 1575˜2150 in Seq. ID No. 5, (18) bases Nos. 2151˜2210 in Seq. ID No. 5, (19) bases Nos. 2211˜2603 in Seq. ID No. 5, (20) bases Nos. 1˜108 in Seq. ID No. 7, (21) bases Nos. 109˜321 in Seq. ID No. 7, (22) bases Nos. 1˜465 in Seq. ID No. 11, (23) bases Nos. 466˜1092 in Seq. ID No. 11, (24) bases Nos. 1108˜1377 in Seq. ID No. 11, (25) bases Nos. 1378˜1968 in Seq. ID No. 11, (26) bases Nos. 3˜221 in Seq. ID No. 17, (27) bases Nos. 222˜284 in Seq. ID No. 17, (28) bases Nos. 285˜623 in Seq. ID No. 17, (29) bases Nos. 1˜120 in Seq. ID No. 9, (30) bases Nos. 136˜408 in Seq. ID No. 9, (31) bases Nos. 409˜966 in Seq. ID No. 9, (32) bases Nos. 1603˜1671 in Seq. ID No. 11.
65. An antisense oligonucleotide or a derivative thereof corresponding to the isolated DNA claim 59.
66. An antisense oligonucleotide or a derivative thereof corresponding to the isolated DNA claim 60.
67. An antisense oligonucleotide or a derivative thereof corresponding to the isolated DNA claim 61.
68. An antisense oligonucleotide or a derivative thereof corresponding to the isolated DNA claim 62.
69. An antisense oligonucleotide or a derivative thereof corresponding to the isolated DNA claim 63.
70. An antisense oligonucleotide or a derivative thereof corresponding to the isolated DNA claim 64.
71. An antibody immunoreactive with the Meltrin of claim 49.
72. An antibody immunoreactive with the Meltrin of claim 50.
73. An antibody immunoreactive with the Meltrin of claim 51.
74. An antibody immunoreactive with the polypeptide of claim 52.
75. An antibody immunoreactive with the polypeptide of claim 53.
76. An antibody immunoreactive with the polypeptide of claim 54.
77. An antibody immunoreactive with the polypeptide of claim 55.
78. An antibody immunoreactive with the polypeptide of claim 56.
79. An antibody immunoreactive with the polypeptide of claim 57.
80. An antibody immunoreactive with the polypeptide of claim 58.
81. A neutralizing antibody according to any one of claims 71-80.
82. A monoclonal antibody according to any one of claims 71-80.
83. An isolated polypeptide comprising an amino acid sequence encoded by a base sequence which hybridizes with a base sequence complementary to the sequence of claim 59.
84. An isolated polypeptide comprising an amino acid sequence encoded by a base sequence which hybridizes with a base sequence complementary to the sequence of claim 60.
85. A DNA sequence which hybridizes with a base sequence complementary to a base sequence selected from the group consisting of: (1) bases Nos. 221˜2929 in Seq. ID No. 1, (2) bases Nos. 1478˜1747 in Seq. ID No. 1, (3) bases Nos. 63˜2822 in Seq. ID No. 3, (4) bases Nos. 1305˜1574 in Seq. ID No. 3, (5) bases Nos. 69˜2603 in Seq. ID No. 5, (6) bases Nos. 1302˜1574 in Seq. ID No. 5, (7) bases Nos. 1˜321 in Seq. ID No. 7, (8) bases Nos. 1˜2058 in Seq. ID No. 11, (9) bases Nos. 1108˜1377 in Seq. ID No. 11, (10) bases Nos. 3˜623 in Seq. ID No. 17, (11) bases Nos. 125˜394 in Seq. ID No. 9, (12) bases Nos. 1˜966 in Seq. ID No. 9, and (13) bases Nos. 136˜408 in Seq. ID No. 9.
86. A DNA sequence which hybridizes with a base sequence complementary to a base sequence selected from the group consisting of: (1) bases Nos. 221˜835 in Seq. ID No. 1, (2) bases Nos. 836˜1462 in Seq. ID No. 1, (3) bases Nos. 1478˜1747 in Seq. ID No. 1, (4) bases Nos. 1748˜2338 in Seq. ID No. 1, (5) bases Nos. 2339˜2401 in Seq. ID No. 1, (6) bases Nos. 1973˜2041 in Seq. ID No. 1, (7) bases Nos. 2402˜2929 in Seq. ID No. 1, (8) bases Nos. 63˜674 in Seq. ID No. 3, (9) bases Nos. 675˜1289 in Seq. ID No. 3, (10) bases Nos. 1305˜1574 in Seq. ID No. 3, (11) bases Nos. 1575˜2180 in Seq. ID No. 3, (12) bases Nos. 2181˜2249 in Seq. ID No. 3, (13) bases Nos. 2250˜2822 in Seq. ID No. 3, (14) bases Nos. 69˜683 in Seq. ID No. 5, (15) bases Nos. 684˜1292 in Seq. ID No. 5, (16) bases Nos. 1302˜1574 in Seq. ID No. 5, (17) bases Nos. 1575˜2150 in Seq. ID No. 5, (18) bases Nos. 2151˜2210 in Seq. ID No. 5, (19) bases Nos. 2211˜2603 in Seq. ID No. 5, (20) bases Nos. 1˜108 in Seq. ID No. 7, (21) bases Nos. 109˜321 in Seq. ID No. 7, (22) bases Nos. 1˜465 in Seq. ID No. 11, (23) bases Nos. 466˜1092 in Seq. ID No. 11, (24) bases Nos. 1108˜1377 in Seq. ID No. 11, (25) bases Nos. 1378˜1968 in Seq. ID No. 11, (26) bases Nos. 3˜221 in Seq. ID No. 17, (27) bases Nos. 222˜284 in Seq. ID No. 17, (28) bases Nos. 285˜623 in Seq. ID No. 17, (29) bases Nos. 1˜120 in Seq. ID No. 9, (30) bases Nos. 136˜408 in Seq. ID No. 9, (31) bases Nos. 409˜966 in Seq. ID No. 9, (32) bases Nos. 1603˜1671 in Seq. ID No. 11.
87. A medical composition comprising Meltrin according to one of claims 49-51, and a medically acceptable carrier.
88. A medical composition comprising an isolated polypeptide according to one of claims 52-58, and a medically acceptable carrier.
89. A medical composition comprising an antagonist to Meltrin, and a medically acceptable carrier.
90. A medical composition according to claim 87, wherein the composition has bone resorption inhibiting activity.
91. A medical composition according to claim 88, wherein the composition has bone resorption inhibiting activity.
92. A medical composition according to claim 89, wherein the composition has bone resorption inhibiting activity.
93. Mouse DNA encoding a polypeptides having a Meltrin function and being obtainable by PCR method using a degenerative sense primer selected from (1) primer consisting of a DNA sequence encoding an amino acid sequence EDCDCG (Seq. ID No. 40), (2) primer consisting of a DNA sequence encoding an amino acid sequence EECDCG (Seq. ID No. 41), and a degenerative antisense primer consisting of a DNA sequence encoding an amino acid sequence KCGKLIC (Seq. ID No. 42).
94. A vector comprising the DNA of claim 59.
95. A vector comprising the DNA of claim 60.
96. A vector comprising the DNA of claim 63.
97. A vector comprising the DNA of claim 64.
98. A cell stably transformed with the vector of claim 94.
99. A cell stably transformed with the vector of claim 95.
100. A cell stably transformed with the vector of claim 96.
101. A cell stably transformed with the vector of claim 97.
102. A method of producing a desired polypeptide comprising culturing a cell selected from the cells of claims 98-101.
103. Human DNA encoding a polypeptide having a meltrin function and being obtainable by PCT method using a primer set selected from: (1) Seq. ID No. 33 as a sense primer and Seq. ID No. 30 as an antisense primer, (2) Seq. ID No. 38 as a sense primer and Seq. ID No. 39 as an antisense primer, and (3) Seq. ID No. 43 as a sense primer and Seq. ID No. 44 as an antisense primer.

Priority Claims (2)

Number	Date	Country	Kind
8-61756	Feb 1996	JP
PCT/JP96/03017	Oct 1996	JP

Parent Case Info

[0001] This application is a continuation of U.S. patent application Ser. No. 09/138,675, filed Aug. 24, 1998, which in turn is a continuation of PCT Application No. PCT/JP96/03017, filed Oct. 17, 1996, which claims priority of Japanese Patent Application No. Hei 8/61756, filed Feb. 23, 1996. The entire disclosure of all of the above applications is hereby incorporated by reference herein.

Continuations (1)

	Number	Date	Country
Parent	09138675	Aug 1998	US
Child	09983531	Oct 2001	US

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (2)

Parent Case Info

Continuations (1)